<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">77274</article-id><article-id pub-id-type="doi">10.7554/eLife.77274</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Pinpointing the tumor-specific T cells via TCR clusters</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-268469"><name><surname>Goncharov</surname><given-names>Mikhail M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268470"><name><surname>Bryushkova</surname><given-names>Ekaterina A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-268471"><name><surname>Sharaev</surname><given-names>Nikita I</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-268472"><name><surname>Skatova</surname><given-names>Valeria D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268473"><name><surname>Baryshnikova</surname><given-names>Anastasiya M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268474"><name><surname>Sharonov</surname><given-names>George V</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-273819"><name><surname>Karnaukhov</surname><given-names>Vadim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273816"><name><surname>Vakhitova</surname><given-names>Maria T</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268475"><name><surname>Samoylenko</surname><given-names>Igor V</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268476"><name><surname>Demidov</surname><given-names>Lev V</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273815"><name><surname>Lukyanov</surname><given-names>Sergey</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-233804"><name><surname>Chudakov</surname><given-names>Dmitriy M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0430-790X</contrib-id><email>chudakovdm@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268477"><name><surname>Serebrovskaya</surname><given-names>Ekaterina O</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03f9nc143</institution-id><institution>Center of Life Sciences, Skolkovo Institute of Science and Technology</institution></institution-wrap><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01dg04253</institution-id><institution>Genomics of Adaptive Immunity Department, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry</institution></institution-wrap><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/050a13t43</institution-id><institution>Department of Molecular Biology, Moscow State University</institution></institution-wrap><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/018159086</institution-id><institution>Pirogov Russian National Research Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00apdsa62</institution-id><institution>Laboratory of Genomics of Antitumor Adaptive Immunity, Privolzhsky Research Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Nizhny Novgorod</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ab9fg88</institution-id><institution>Oncodermatology Department, NN Blokhin Russian Cancer Research Center</institution></institution-wrap><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Washington</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023vrr657</institution-id><institution>Indian Institute of Science Education and Research (IISER)</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>04</day><month>04</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e77274</elocation-id><history><date date-type="received" iso-8601-date="2022-01-22"><day>22</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-04-04"><day>04</day><month>04</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-01-30"><day>30</day><month>01</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.01.30.478375"/></event></pub-history><permissions><copyright-statement>© 2022, Goncharov et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Goncharov et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-77274-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-77274-figures-v3.pdf"/><abstract><p>Adoptive cell transfer (ACT) is a promising approach to cancer immunotherapy, but its efficiency fundamentally depends on the extent of tumor-specific T cell enrichment within the graft. This can be estimated via activation with identifiable neoantigens, tumor-associated antigens (TAAs), or living or lysed tumor cells, but these approaches remain laborious, time-consuming, and functionally limited, hampering clinical development of ACT. Here, we demonstrate that homology cluster analysis of T cell receptor (TCR) repertoires efficiently identifies tumor-reactive TCRs allowing to: (1) detect their presence within the pool of tumor-infiltrating lymphocytes (TILs); (2) optimize TIL culturing conditions, with IL-2<sub>low</sub>/IL-21/anti-PD-1 combination showing increased efficiency; (3) investigate surface marker-based enrichment for tumor-targeting T cells in freshly isolated TILs (enrichment confirmed for CD4<sup>+</sup> and CD8<sup>+</sup> PD-1<sup>+</sup>/CD39<sup>+</sup> subsets), or re-stimulated TILs (informs on enrichment in 4-1BB-sorted cells). We believe that this approach to the rapid assessment of tumor-specific TCR enrichment should accelerate T cell therapy development.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer immunotherapy</kwd><kwd>T cell receptor repertoires</kwd><kwd>PD-1<sup>+</sup>/CD39<sup>+</sup></kwd><kwd>tumor-infiltrating lymphocytes</kwd><kwd>TCR clusters</kwd><kwd>tumor-associated antigens</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Ministry of Science and Higher Education of the Russian Federation</institution></institution-wrap></funding-source><award-id>075-15-2020-807</award-id><principal-award-recipient><name><surname>Chudakov</surname><given-names>Dmitriy M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Cluster analysis reveals convergent T cell clones reacting to tumor antigens, enabling intelligent optimization of cancer immunotherapy.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tumors develop diverse mechanisms of immune evasion, including the generation of hypoxic conditions (<xref ref-type="bibr" rid="bib36">Petrova et al., 2018</xref>), inflammation (<xref ref-type="bibr" rid="bib21">Grivennikov et al., 2010</xref>), establishment of an immunosuppressive microenvironment (<xref ref-type="bibr" rid="bib67">Ziani et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Binnewies et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Vijayan et al., 2017</xref>; <xref ref-type="bibr" rid="bib32">Moesta et al., 2020</xref>), downregulation of antigen presentation (<xref ref-type="bibr" rid="bib27">Kvistborg and Yewdell, 2018</xref>; <xref ref-type="bibr" rid="bib52">Seliger et al., 2000</xref>; <xref ref-type="bibr" rid="bib58">Spranger et al., 2015</xref>), promotion of regulatory T cell (T<sub>reg</sub>) infiltration (<xref ref-type="bibr" rid="bib13">Curiel et al., 2004</xref>) and outgrowth (<xref ref-type="bibr" rid="bib1">Adeegbe and Nishikawa, 2013</xref>), and induction of T cell dysfunction (<xref ref-type="bibr" rid="bib60">Thommen and Schumacher, 2018</xref>). The infusion of large numbers of expanded autologous tumor-reactive T cells—typically after the implementation of lymphodepleting regimens—represents a powerful therapeutic option that may override these immunosuppressive mechanisms. Clinical protocols for such adoptive cell transfer (ACT) therapeutic strategies (<xref ref-type="bibr" rid="bib25">Klebanoff et al., 2005</xref>), inspired by the pioneering work of Steven Rosenberg’s group (<xref ref-type="bibr" rid="bib57">Spiess et al., 1987</xref>; <xref ref-type="bibr" rid="bib48">Rosenberg et al., 1994</xref>; <xref ref-type="bibr" rid="bib47">Rosenberg et al., 1988</xref>), are now being actively developed and used to treat patients (<xref ref-type="bibr" rid="bib51">Sarnaik et al., 2021</xref>; <xref ref-type="bibr" rid="bib15">Dudley et al., 2003</xref>; <xref ref-type="bibr" rid="bib11">Chapuis et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Kelderman et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Rosenberg and Restifo, 2015</xref>).</p><p>There is accordingly great demand for methods for the enrichment of autologous tumor antigen-specific T cells for use in ACT protocols. Current techniques rely on the identification of patient-specific peptide neoantigens, which are then used for the functional characterization and selection of cultured tumor-infiltrating lymphocytes (TILs) (<xref ref-type="bibr" rid="bib64">Yossef et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Leko et al., 2019</xref>). Alternatively, since the identification of unique neoantigens is costly, time-consuming, and functionally limited in terms of the spectra of identifiable antigens, cultured autologous tumor tissue can be used as a source of antigen-specific stimulus (<xref ref-type="bibr" rid="bib53">Seliktar-Ofir et al., 2017</xref>). Certain cell-surface markers of ongoing and chronic activation such as PD-1, CD39, CD69, CD103, or CD137 may also help to delineate T cell subpopulations (typically CD8<sup>+</sup>) that are enriched for clonally expanded tumor-reactive T cells (<xref ref-type="bibr" rid="bib22">Gros et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Duhen et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Murray et al., 2016</xref>), therefore culturing selected TIL subsets, such as PD-1<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib23">Inozume et al., 2010</xref>), is a feasible option. In all of these scenarios, however, there is the need for a robust method that enables estimation of enrichment of the transplanted cells with tumor-specific T cells based on the T cell receptor (TCR) repertoire without prior knowledge of TCR specificities.</p><p>The ongoing adaptive immune response is often driven by groups of T cell clones with highly homologous TCR sequences (clusters) that recognize the same epitopes (<xref ref-type="bibr" rid="bib40">Pogorelyy et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Dash et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Glanville et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Pogorelyy et al., 2018</xref>). However, clusters of highly similar TCRs also abundantly arise from the so-called ‘public’ variants having high probability of being generated in the course of V(D)J recombination (<xref ref-type="bibr" rid="bib62">Venturi et al., 2011</xref>; <xref ref-type="bibr" rid="bib17">Elhanati et al., 2018</xref>). ALICE approach evaluates the number of ‘neighbors’ relative to the baseline expectation from V(D)J recombination statistics, and retains the node clonotypes of the TCR clusters with higher numbers of neighbors than expected by a null model of recombination (<xref ref-type="bibr" rid="bib40">Pogorelyy et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Dash et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Glanville et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Pogorelyy et al., 2018</xref>). This approach is highly efficient to capture clonotypes involved in the current immune response from a single repertoire snapshot, and does not require longitudinal data collection (<xref ref-type="bibr" rid="bib40">Pogorelyy et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Dash et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Glanville et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Pogorelyy et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Pogorelyy and Shugay, 2019</xref>).</p><p>Here, we have employed ALICE-based cluster analysis to identify groups of TCR clonotypes involved in the anti-tumor immune response. We demonstrate that this approach successfully pinpoints known tumor-associated antigens (TAAs)-specific TCRs among TIL repertoires in HLA-A*02 melanoma patients. Furthermore, we find that the number of cluster-related clonotypes and the proportion of the bulk TIL repertoire that they occupy grow significantly after anti-PD-1 immunotherapy. We next investigate the TCR content in sorted CD4<sup>+</sup>CD39<sup>+</sup>PD1<sup>+</sup> and CD8<sup>+</sup>CD39<sup>+</sup>PD1<sup>+</sup> TILs, and show that these subsets are prominently enriched for TCR clusters, a substantial fraction of which consists of tumor-specific TCRs. These results provide a rationale for focusing on CD39<sup>+</sup>PD1<sup>+</sup> TILs in adoptive cancer therapy. Finally, we show that repertoire analysis facilitates optimization of TIL culturing conditions, and allows estimation of the extent of tumor-specific T cell enrichment in cultured donor cells and sorted TAA-activated T cells. Altogether, our findings strongly support the use of cluster TCR analysis as a powerful tool with practical applications in clinical ACT.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TIL clusters include TAA-specific TCRs and grow after immunotherapy</title><p>We first analyzed published TIL TCR beta chain (TCRβ) repertoires obtained before and after anti-PD-1 immunotherapy for two cohorts comprising 21 and 8 patients with cutaneous melanoma (<xref ref-type="bibr" rid="bib44">Riaz et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Tumeh et al., 2014</xref>). Using the ALICE algorithm (<xref ref-type="bibr" rid="bib40">Pogorelyy et al., 2019</xref>), we were able to identify clusters of convergent TCRβ clonotypes in all patients. The number of cluster-related clonotypes significantly increased after therapy in both cohorts (p = 0.019 and 0.038, respectively; <xref ref-type="fig" rid="fig1">Figure 1a and b</xref>), which might reflect treatment-dependent expansion of convergent antigen-specific TILs. At the same time, no statistically significant differences were observed between responders, stable disease, and progressive disease groups.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Melanoma tumor-infiltrating lymphocyte (TIL) T cell receptor (TCR) clusters before and after immunotherapy.</title><p>(<bold>a</bold>, <bold>b</bold>) Normalized counts of cluster-related TCRβ clonotypes from metastatic melanoma samples before and after anti-PD-1 therapy from datasets published in (<bold>a</bold>) (<xref ref-type="bibr" rid="bib44">Riaz et al., 2017</xref>) and (<bold>b</bold>) (<xref ref-type="bibr" rid="bib61">Tumeh et al., 2014</xref>). (<bold>c</bold>) Cumulative frequency of VDJdb-matched tumor-associated antigen (TAA)-specific clonotypes within the whole repertoire (in bulk) and within cluster-related clonotypes (ALICE hits) of patients that have at least one VDJdb-matched cluster (N = 8 patients) from the two published datasets. (<bold>d</bold>) TCRβ clusters from patient pt44 (<xref ref-type="bibr" rid="bib44">Riaz et al., 2017</xref>). Each dot represents individual TCRβ clonotype. Dot size is proportional to the clonotype frequency in the bulk TCRβ repertoire. VDJdb-matched TAA-specific clonotypes are colored in red. (<bold>e, f</bold>) TCRβ clusters before and after therapy for each patient from (<bold>e</bold>) (<xref ref-type="bibr" rid="bib44">Riaz et al., 2017</xref>) and (<bold>f</bold>) (<xref ref-type="bibr" rid="bib61">Tumeh et al., 2014</xref>). One dot corresponds to one cluster. Y axis shows the size of corresponding clusters (e.g. cumulative frequency of clonotypes within a cluster, % of the whole repertoire). VDJdb-matched TAA-specific clusters are colored in red. N = number of biological replicates in each group. Data in (<bold>a</bold>) were analyzed with paired t-test; b, c were analyzed with the Wilcoxon test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-fig1-v3.tif"/></fig><p>A VDJdb database (<xref ref-type="bibr" rid="bib55">Shugay et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Bagaev et al., 2020</xref>) search identified cluster-related clonotypes that are highly similar or identical to known TCRβ variants specific to the HLA-A*02-restricted melanoma-associated antigens Melan-A (Melan-A<sub>aa26-35</sub> - ELAGIGILTV) and NY-ESO-1 (NY-ESO-1<sub>aa157-165</sub> - SLLMWITQC) in 20% and 50% of patients from the <xref ref-type="bibr" rid="bib44">Riaz et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Tumeh et al., 2014</xref>, cohorts, respectively. Cluster-related clonotypes were enriched for TAA-specific TCRβ variants compared to the bulk TCR repertoire, indicating that cluster analysis can capture clonotypes involved in an ongoing anti-tumor immune response (<xref ref-type="fig" rid="fig1">Figure 1c and d</xref>). <xref ref-type="fig" rid="fig1">Figure 1d</xref> shows identified TCR clusters for one of the patients after immunotherapy. Summary for the count and size of TCR clusters before and after immunotherapy for each patient is shown in <xref ref-type="fig" rid="fig1">Figure 1e and f</xref>.</p><p>Notably, the HLA genotypes of the patients for these two cohorts were unknown. Since VDJdb currently includes limited diversity of HLA contexts, we believe that a much higher proportion of cluster-related clonotypes will be assigned to TAA specificities with the accumulation of TCR specificity data from more diverse HLA contexts.</p></sec><sec id="s2-2"><title>CD39<sup>+</sup>PD1<sup>+</sup> TILs are enriched with clonal, convergent, and tumor-specific TCRs</title><p>It was previously reported that CD39<sup>+</sup> and PD-1<sup>+</sup> TIL subsets can be enriched for tumor-specific T cells (<xref ref-type="bibr" rid="bib22">Gros et al., 2014</xref>; <xref ref-type="bibr" rid="bib23">Inozume et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Balança et al., 2021</xref>; <xref ref-type="bibr" rid="bib30">Li, 2020</xref>; <xref ref-type="bibr" rid="bib59">Thommen et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Simoni et al., 2018</xref>; <xref ref-type="bibr" rid="bib35">Pauken et al., 2021</xref>; <xref ref-type="bibr" rid="bib66">Zhu et al., 2021</xref>). To verify whether there is concurrent enrichment with convergent TCR clusters, we performed fluorescence-activated cell sorting (FACS) of CD39<sup>+</sup>PD-1<sup>+</sup> (double-positive [DP]) and non-DP CD4<sup>+</sup> and CD8<sup>+</sup> T cells from TILs freshly isolated from lymph node metastases from eight melanoma patients (<xref ref-type="fig" rid="fig2">Figure 2a</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>). Overall, TIL composition was skewed toward greater prevalence of CD4<sup>+</sup> T cells, although cells with the DP phenotype were more prevalent among CD8<sup>+</sup> TILs compared to CD4<sup>+</sup> cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a,b</xref>). TCRβ repertoire analysis revealed increased clonality and cluster enrichment for both CD4<sup>+</sup> and CD8<sup>+</sup> DP TILs compared to the corresponding non-DP subsets (<xref ref-type="fig" rid="fig2">Figure 2b–g</xref>), with greater clonality among CD8<sup>+</sup> TILs than CD4<sup>+</sup> TILs regardless of immune checkpoint expression status (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2c,d</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>T cell receptor (TCR) clusters in CD39<sup>+</sup>PD1<sup>+</sup> tumor-infiltrating lymphocytes (TILs).</title><p>(<bold>a</bold>) The experimental workflow. (<bold>b–g</bold>) TCRβ repertoire analysis for CD8<sup>+</sup> (<bold>b, d, f</bold>) and CD4<sup>+</sup> (<bold>c, e, g</bold>) double-positive (DP) and non-DP TIL subsets sorted from metastatic lymph nodes of eight melanoma patients. Panels show repertoire clonality calculated as [1 − Normalized Shannon-Wiener index] (<bold>b, c</bold>), normalized counts (<bold>d, e</bold>), and cumulative frequency of cluster-related clonotypes, that is, total weight of all clusters as a proportion of TCRβ repertoire (<bold>f, g</bold>). Paired t-test. (<bold>h</bold>) TCRβ clusters identified in repertoires obtained from fresh-frozen tumor (FFT) samples, and sorted CD8<sup>+</sup> DP and non-DP TILs for HLA-A*02 patient mp26. VDJdb-matched TAA-specific clusters are colored in red. (<bold> i</bold>,<bold> j</bold>) Cumulative frequency of (<bold>i</bold>) VDJdb-matched TAA-specific clonotypes and (<bold>j</bold>) VDJdb-matched TAA-specific cluster-related clonotypes within CD8<sup>+</sup> DP, CD8<sup>+</sup> non-DP, and FFT TCRβ repertoires of patient mp26. One-way ANOVA, Bonferroni multiple comparisons correction. (<bold>k</bold>,<bold> l</bold>) Proportion of CD137<sup>+</sup> cells among CD8<sup>+</sup> T cells (<bold>k</bold>) and proportion of VDJdb-matched TAA-specific clonotypes in sorted CD137<sup>+</sup>CD8<sup>+</sup> T cells (<bold>l</bold>) in DP and non-DP TILs from patient mp26 that were cultured and re-stimulated with TAA-loaded or control dendritic cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>(<bold>a</bold>) Fluorescence-activated cell sorting (FACS) gating for sorting of CD8<sup>+</sup> and CD4<sup>+</sup> CD39<sup>+</sup>PD-1<sup>+</sup> double-positive (DP) and non-DP T cells from briefly cultured melanoma tumor-infiltrating lymphocytes (TILs) and single-cell suspensions prepared from tumor samples (<bold>b,c</bold>).</title><p>Cumulative frequency of cluster-related Melan-A-specific T cell receptors (TCRs) (<bold>b</bold>) and all Melan-A-specific TCRs (<bold>c</bold>) in CD8<sup>+</sup> DP and CD8<sup>+</sup> non-DP TIL repertoires from patient mp41. (<bold>d</bold>) Number of ALICE hits significantly correlates with the number of input clonotypes. TCR repertoires of melanoma TILs before and after anti-PD-1 immunotherapy were used for the analysis (public datasets from <xref ref-type="bibr" rid="bib44">Riaz et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Tumeh et al., 2014</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-fig2-figsupp1-v3.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Characteristics of sorted tumor-infiltrating lymphocytes (TILs).</title><p>(<bold>a</bold>) Fraction of CD8<sup>+</sup> and CD4<sup>+</sup> cells out of all tumor-infiltrating CD3<sup>+</sup>T cells. (<bold>b</bold>) Fraction of CD39<sup>+</sup>PD-1<sup>+</sup> cells consisting of CD8<sup>+</sup> and CD4<sup>+</sup> TILs. (<bold>c</bold>,<bold> d</bold>) Clonality (calculated as [1 − Normalized Shannon-Wiener index]) of CD8<sup>+</sup> and CD4<sup>+</sup> (<bold>c</bold>) doube-positive (DP) and (<bold>d</bold>) non-DP TILs. N = number of tested patients. Data analyzed by paired t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-fig2-figsupp2-v3.tif"/></fig></fig-group><p>For TILs obtained from HLA-A*02-positive patient mp26, with BRAF<sup>wt</sup> melanoma, a VDJdb search identified three TCR clusters that included A*02-Melan-A<sub>aa26-35</sub>-specific clonotypes (<xref ref-type="fig" rid="fig2">Figure 2h</xref>). Clonotypes matching to Melan-A-specific VDJdb entries were prominently enriched within the CD8<sup>+</sup> DP subset (about 1.5% of repertoire), compared to fresh-frozen tumor (FFT) tissue and to the CD8<sup>+</sup> non-DP subset (<xref ref-type="fig" rid="fig2">Figure 2i</xref>). Most of these clonotypes belonged to TCR clusters, and such Melan-A-specific cluster-related clonotypes constituted about 1% of CD8<sup>+</sup> DP subset repertoire (<xref ref-type="fig" rid="fig2">Figure 2j</xref>).</p><p>Similar results were obtained for another BRAF<sup>wt</sup> HLA-A*02-positive patient, pt41 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b,c</xref>), where TCR repertoires of CD8<sup>+</sup> DP and CD8<sup>+</sup> non-DP subsets were compared. We concluded that the CD39<sup>+</sup>PD1<sup>+</sup> fraction is enriched for large and convergent T cell clones that are involved in an ongoing tumor-specific immune response, a substantial portion of which are detectable via cluster TCR analysis.</p><p>To functionally confirm our findings, we used the CD137 (4-1BB) upregulation assay. Sorted DP and non-DP TIL subsets from patient mp26 were cultured for 2 weeks and stimulated with autologous monocyte-derived dendritic cells loaded with a TAA peptide mix. CD8<sup>+</sup>CD137<sup>high</sup> subsets were subsequently quantified with flow cytometry and sorted for TCRβ library preparation.</p><p>As shown in <xref ref-type="fig" rid="fig2">Figure 2k</xref>, the proportion of CD137<sup>high</sup> cells was higher in cultured DP cells, but we found no difference between T cells stimulated by TAA-loaded or control dendritic cells. At the same time, TCRβ repertoire analysis revealed that the CD137<sup>high</sup> fraction of TAA-stimulated CD8<sup>+</sup> DP—but not non-DP or control DP—cells was enriched with known Melan-A-specific clonotypes (<xref ref-type="fig" rid="fig2">Figure 2l</xref>). These clonotypes included a TAA-reactive TCRβ variant, CSARVGNQPQHF-TRBV20-TRBJ1-5, which was previously detected in cluster analysis of non-cultured CD8<sup>+</sup> DP cells, and variant CASSGGMGQPQHF-TRBV19-TRBJ1-5, which is homologous to another cluster. TAA-specific clonotypes cumulatively occupied ~13% of the CD137<sup>high</sup> fraction of the cultured and TAA-activated DP TILs. These results underscore the importance of TCR repertoire analysis of responding cells, even in the apparent absence of a quantifiable difference between antigen and control conditions, and demonstrate that CD137 marker analysis on its own is insufficiently informative.</p></sec><sec id="s2-3"><title>TCR cluster analysis facilitates optimization of TIL culturing conditions</title><p>We next investigated the effect of distinct TIL culture conditions on the expansion of tumor-reactive T cells, including concentration of IL-2 (stimulates expansion of both conventional T cells and T<sub>reg</sub>), and presence of IL-21 (plays a key role in the development and maintenance of memory CD8<sup>+</sup> T cells, inhibits T<sub>reg</sub> proliferation), anti-PD-1 antibody (blocks inhibitory interaction of T cells’ PD-1 with PD-L1), and IFNγ (activates antigen presentation and supports type 1 immune response). Four distinct TIL culture conditions included: IL-2<sub>high</sub>, IL-2<sub>low</sub>/IL-21, IL-2<sub>low</sub>/IL-21/anti-PD-1, and IL-2<sub>low</sub>/IL-21/anti-PD-1/IFNγ (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), where the anti-PD-1 agent employed was nivolumab and the concentration of IL-2 in the low and high conditions was 100 and 3000 IU/mL, respectively. For each condition, we analyzed TCRβ repertoires of TILs independently cultured from 12 tumor fragments collected from patient mp26. TCR clusters identified from all samples were joined and visualized along with the non-cultured FFT, DP CD8<sup>+</sup>, and non-DP CD8<sup>+</sup>, repertoires (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). As a readout, we used the following:</p><list list-type="roman-lower"><list-item><p>normalized count of cluster-related clonotypes (<xref ref-type="fig" rid="fig3">Figure 3b</xref>),</p></list-item><list-item><p>cumulative proportion of the repertoire occupied by Melan-A-specific TCRβ clusters (clusters predominantly comprising VDJdb-defined Melan-A-specific clonotypes) (<xref ref-type="fig" rid="fig3">Figure 3c</xref>), and</p></list-item><list-item><p>the number of differentially expanded clonotypes compared to pan-activating IL-2<sub>high</sub> culture conditions, and the proportion of such expanded clonotypes that were also initially detected among CD8<sup>+</sup> DP TILs (<xref ref-type="fig" rid="fig3">Figure 3d</xref>).</p></list-item></list><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Influence of culture conditions on tumor-infiltrating lymphocytes (TILs) and T cell receptor (TCR) clusters.</title><p>(<bold>a</bold>) Combined TCRβ clusters for fresh-frozen tumor (FFT), CD8<sup>+</sup> double-positive (DP), CD8<sup>+</sup> non-DP, and TILs cultured in four different conditions from metastatic tumor sample of patient mp26. Left: colors indicate VDJdb-defined clonotype specificities. Right: colors indicate the sample of origin. (<bold>b–e</bold>) TCRβ repertoire analysis for patient mp26 TILs cultured in four distinct conditions. Panels show (<bold>b</bold>) normalized counts of cluster-related TCRβ clonotypes, (<bold>c</bold>) proportion of the repertoire occupied by Melan-A-specific TCRβ clusters, (<bold>d</bold>) count and subset matching of clonotypes preferentially expanded compared to the IL-2<sub>high</sub> condition, and (<bold>e</bold>) the count of CD8<sup>+</sup> DP matched clonotypes among the top 1500 clonotypes. N = number of separate tumor fragments. (<bold>f</bold>) Fraction of regulatory T cells (T<sub>reg</sub>s) (CD25<sup>+</sup>CD127<sup>-</sup>FoxP3<sup>+</sup>) among CD4<sup>+</sup> T cells in cultured TILs from patient mp41 in each culture condition. (<bold>g</bold>) TIL counts relative to IL-2<sub>high</sub> culture conditions; n = 4 patients. (<bold>h</bold>) CD8<sup>+</sup>/CD4<sup>+</sup> ratio for TILs from patient mp41 in each culture condition. Data in b ,c, f, g were analyzed with one-way ANOVA, Bonferroni multiple comparisons correction, with each condition compared to the IL-21/IL-2<sub>low</sub>/anti-PD-1 condition. Data in the panel (<bold>e</bold>) was analyzed with Kruskal-Wallis test, Dunn’s multiple comparison test, with each group compared to IL-21/IL-2<sub>low</sub>/anti-PD-1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Expansion of tumor-infiltrating lymphocyte (TIL) subtypes in different cultivation conditions.</title><p>(<bold>a</bold>) Experimental pipeline for evaluating CD39<sup>+</sup>PD-1<sup>+</sup> T cell clonotypes expansion from bulk melanoma TILs cultivated in different conditions. (<bold>b</bold>) Number of T cell receptor (TCR) clonotypes preferentially expanded in bulk TILs of patient mp34 under various culture conditions compared to classical IL-2<sub>high</sub> conditions. (<bold>c</bold>,<bold> d</bold>) Fraction of regulatory T cells (T<sub>reg</sub>s) (gated as CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>-</sup>FoxP3<sup>+</sup>) among CD4<sup>+</sup> T cells of patients (<bold>c</bold>) mp42 and (<bold>d</bold>) mp32. (<bold>e</bold>,<bold> f</bold>) Proportion of CD127<sup>high</sup>CD25<sup>low</sup> cells among (<bold>e</bold>) CD4<sup>+</sup> and (<bold>f</bold>) CD8<sup>+</sup> TIL subsets from patient mp41. Data in c, e, f analyzed by one-way ANOVA, Bonferroni’s multiple comparisons test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-fig3-figsupp1-v3.tif"/></fig></fig-group><p>The IL-2<sub>low</sub>/IL-21/anti-PD-1 combination yielded the greatest number of cluster-related clonotypes and the highest cumulative proportion of Melan-A-specific clusters out of all culture conditions, as well as compared to initial non-cultured FFT samples (<xref ref-type="fig" rid="fig3">Figure 3b and c</xref>). Addition of IFNγ did not further enhance the expansion of potentially tumor-specific clones.</p><p>We utilized edgeR (<xref ref-type="bibr" rid="bib45">Robinson et al., 2010</xref>) software, which was initially designed for differential gene expression analysis, to identify clonotypes that were significantly expanded in tumor fragment cultures in the presence of IL-21 and IL-2<sub>low</sub> (either with or without nivolumab and IFNγ) compared to classical pan-activating IL-2<sub>high</sub> culture conditions. The IL-2<sub>low</sub>/IL-21/anti-PD-1 combination yielded the highest number of reproducibly expanded clonotypes, 60% of which were detected among initial non-cultured CD8<sup>+</sup> DP TILs (<xref ref-type="fig" rid="fig3">Figure 3d</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b</xref>). The overall count of such CD8<sup>+</sup> DP-matched clonotypes was also highest for this combination (<xref ref-type="fig" rid="fig3">Figure 3e</xref>). These results show the positive influence of PD-1 inhibition on the proliferative potential of CD8<sup>+</sup>CD39<sup>+</sup>PD-1<sup>+</sup> T cells. We also noted a slight increase in the number of CD8<sup>+</sup> non-DP matched clonotypes which were expanded in these same conditions—10 clonotypes, compared to three clonotypes in IL-2<sub>low</sub>/IL-21 without nivolumab (<xref ref-type="fig" rid="fig3">Figure 3d</xref>)—which can be explained by nivolumab-dependent expansion of PD-1<sup>+</sup>CD39<sup>-</sup> T cells.</p></sec><sec id="s2-4"><title>IL-2<sub>low</sub>/IL-21/anti-PD-1 culture conditions stimulate TIL proliferation without T<sub>reg</sub> expansion</title><p>T<sub>reg</sub>s are known to hamper anti-cancer immune responses elicited by ex vivo expanded TILs (<xref ref-type="bibr" rid="bib31">Melief et al., 2017</xref>). This immunosuppression may be overcome by CD25<sup>+</sup> T cell depletion (<xref ref-type="bibr" rid="bib29">Li et al., 2010</xref>). Alternatively, T<sub>reg</sub> expansion may be suppressed by IL-21 (<xref ref-type="bibr" rid="bib50">Santegoets et al., 2013</xref>). To more comprehensively characterize the distinct TIL culture conditions described above, we compared their capacity to support or suppress T<sub>reg</sub> expansion and overall T cell expansion. Predictably, IL-2 alone yielded the highest proportion of T<sub>reg</sub> (CD4<sup>+</sup>CD25<sup>high</sup>CD127<sup>low</sup>FoxP3<sup>high</sup> cells) cells. In line with prior findings (<xref ref-type="bibr" rid="bib8">Bonnet et al., 2016</xref>), IL-2<sub>low</sub> created preferential conditions for selective T<sub>reg</sub> expansion, while the addition of IL-21 drastically reduced the proportion of T<sub>reg</sub>s among CD4<sup>+</sup> TILs (<xref ref-type="fig" rid="fig3">Figure 3f</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1с,d</xref>).</p><p>IL-21 was previously demonstrated to promote the expansion of T cells with a memory phenotype (<xref ref-type="bibr" rid="bib3">Allard et al., 2007</xref>). We also noted a significant increase in the number of memory phenotype (<xref ref-type="bibr" rid="bib10">Carrette and Surh, 2012</xref>) CD127<sup>high</sup> cells among CD4<sup>+</sup> lymphocytes in IL-21<sup>+</sup> conditions regardless of the presence or absence of nivolumab (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1e</xref>). Remarkably, CD8<sup>+</sup> TILs displayed significant CD127<sup>high</sup> enrichment only upon simultaneous introduction of IL-21 and nivolumab (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1f</xref>). These results reveal the synergistic action of IL-21 and disruption of PD-1-dependent signaling by nivolumab on expansion of CD8<sup>+</sup> memory T cells.</p><p>Regarding overall proliferative potential, the highest T cell count was evident for IL-2<sub>high</sub> conditions, although we observed comparable numbers in the IL-2<sub>low</sub> cultures (<xref ref-type="fig" rid="fig3">Figure 3g</xref>). The presence of IL-21 stifled IL-2-dependent TIL proliferation, as previously reported for human CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib18">Ferrari-Lacraz et al., 2008</xref>). On the other hand, IL-21 was favorable for expansion of CD8<sup>+</sup> TILs, whereas IL-2 alone favored CD4<sup>+</sup> cell growth (<xref ref-type="fig" rid="fig3">Figure 3h</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we demonstrate that rational TCR clustering can be used to identify tumor-specific T cell clones and estimate their relative enrichment among TILs. Starting with published TCR repertoire data from melanoma tumors, we identified clusters of convergent TCR clonotypes, which increased in numbers and total frequency after anti-PD-1 immunotherapy. We next found significant enrichment of convergent TCR clusters in PD1<sup>+</sup>CD39<sup>+</sup> subpopulations of both CD4<sup>+</sup> and CD8<sup>+</sup> TILs, which were previously shown to be enriched in terms of tumor reactivity (<xref ref-type="bibr" rid="bib30">Li, 2020</xref>; <xref ref-type="bibr" rid="bib56">Simoni et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Kortekaas et al., 2020</xref>). These findings are further supported by the data we obtained for cases where we know the HLA context, as well as some TCR clonotypes of interest and their cognate antigens. A VDJdb database search successfully identified TCR variants specific to TAA antigens in HLA-A*02-positive patients, where approximately half of the clusters could be matched to known Melan-A-specific sequences.</p><p>The cumulative frequency of such Melan-A specific clusters within the CD8<sup>+</sup> DP population was only slightly lower than the total frequency of all identified Melan-A specific TCRs, indicating that our approach was able to identify most of the high-frequency tumor-specific clonotypes.</p><p>It should be noted that Melan A-specific T cells have unusually high frequency in melanoma patients, and even in healthy individuals with HLA-A*02 allele (<xref ref-type="bibr" rid="bib37">Pittet et al., 1999</xref>; <xref ref-type="bibr" rid="bib42">Przybyla et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Alanio et al., 2010</xref>). Also, Melan A-specific T cell clones in some cases represent predominant population in melanoma TILs (<xref ref-type="bibr" rid="bib43">Ramirez-Montagut et al., 2000</xref>) and are present at high frequency in melanoma-infiltrated lymph nodes (<xref ref-type="bibr" rid="bib46">Romero et al., 1998</xref>). This may mean that using Melan A-specific clonotypes as a model is overestimating the sensitivity of our approach. On the other hand, in our data, as well as in public datasets we used in this paper, there are other clusters of comparable size that are not identified as Melan A-specific, which means that there are other specificities with similar behavior.</p><p>It should be also noted that TCR clusters are an essential feature of a convergent immune response that involves several homologous clonotypes. For those cases where a single T cell clone dominates in response to a particular antigen and/or homologous ‘neighbors’ are absent due to the very low probability of convergent TCR generation (<xref ref-type="bibr" rid="bib14">Dash et al., 2017</xref>), cluster analysis may miss some of the tumor-reactive TCRs. Nevertheless, our results demonstrate the overall power of this approach, which is applicable in those situations where specific antigens are unknown.</p><p>We describe one potential implementation of our approach by using it to optimize conditions for ex vivo TIL expansion. In particular, TILs cultured in IL-21<sup>+</sup> conditions demonstrated the highest number of cluster-related TCRs, which is indicative of a more prominent influence of antigen-driven TCR selection. We speculate that IL-21 exerts its influence in our culture system both at the antigen-presentation stage (as MHCI- and, to a lesser extent, MHC II-restricted antigen presentation by tumor cells occurs while tumor fragments are cultured ex vivo) (<xref ref-type="bibr" rid="bib19">Gagnon et al., 2008</xref>) and at the expansion stage, where IL-21 selectively promotes the expansion of non-T<sub>reg</sub> populations. The consequences of in vitro PD-1 blockade are less well understood. The in vitro application of an anti-PD1 antibody was previously shown to induce IFNγ and TNFα secretion by PD1-expressing CD8<sup>+</sup> TILs (<xref ref-type="bibr" rid="bib34">Park et al., 2019</xref>). In our work, we found a greater increase in abundance of cluster-related and tumor-specific TCRs for cells cultured in IL-21<sup>+</sup>/anti-PD-1 conditions compared to IL-21<sup>+</sup> alone.</p><p>We expect that this straightforward TCR repertoire-based approach to estimation of TIL enrichment with tumor-reactive clones will accelerate clinical development of adoptive T cell therapy. At the R&amp;D stage, this approach could greatly facilitate the selection of optimal TIL subsets and optimization of TIL culturing conditions and downstream enrichment procedures. And within clinical pipelines, such analyses should make it possible to estimate tumor-reactive TIL abundance at the level of individual tumor samples, both before and after culturing and/or enrichment. As the field of T cell therapy advances toward the ability to determine the clonal specificities and phenotypes that can effectively fight each individual patient’s tumor, methods for grouping convergent TCRs that respond to the same tumor antigens will become an essential part of the toolbox for rationally designed T cell therapy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Human AB serum</td><td align="left" valign="bottom">PanBiotech, Germany</td><td align="left" valign="bottom">P30-2901</td><td align="left" valign="bottom">Cell culture medium component</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">IL-2 (Ronkoleukine)1,000,000 IU/mL</td><td align="left" valign="bottom">BiotechSpb, Russia</td><td align="left" valign="bottom">–</td><td align="char" char="ndash" valign="bottom">100–3000 IU/mL</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RPMI-1640</td><td align="left" valign="bottom">PanEco, Russia</td><td align="left" valign="bottom">C310</td><td align="left" valign="bottom">Cell culture medium</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES, pH 7.2, 1 M</td><td align="left" valign="bottom">PanEco, Russia</td><td align="left" valign="bottom">Ф134</td><td align="left" valign="bottom">25 µM/mL</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin/streptomycin</td><td align="left" valign="bottom">Gibco, USA, Waltham, Massachusetts</td><td align="left" valign="bottom">10378016</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gentamicin</td><td align="left" valign="bottom">Gibco, USA, Waltham, Massachusetts</td><td align="left" valign="bottom">15750–037</td><td align="char" char="." valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Non-essential amino acids mix</td><td align="left" valign="bottom">Gibco, USA, Waltham, Massachusetts</td><td align="left" valign="bottom">11140–035</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">GlutaMAX</td><td align="left" valign="bottom">Gibco, USA, Waltham, Massachusetts</td><td align="left" valign="bottom">35050–061</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">β-Mercaptoethanol</td><td align="left" valign="bottom">Gibco, USA, Waltham, Massachusetts</td><td align="left" valign="bottom">31350010</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium pyruvate</td><td align="left" valign="bottom">Gibco, USA, Waltham, Massachusetts</td><td align="left" valign="bottom">11360–070</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RLT cell lysis buffer</td><td align="left" valign="bottom">Qiagen, The Netherlands</td><td align="left" valign="bottom">160046763</td><td align="left" valign="bottom">Sample:RLT ratio &gt;1 : 3.5</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">IL-21</td><td align="left" valign="bottom">SCI-STORE, Russia</td><td align="left" valign="bottom">PSG260-10</td><td align="char" char="." valign="bottom">50 ng/mL</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Nivolumab(Opdivo 10 mg/mL)</td><td align="left" valign="bottom">Bristol-Myers Squibb, USA, New York City, New York</td><td align="left" valign="bottom">NDC 00003-3772-11</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-CD3/CD28 Dynabeads</td><td align="left" valign="bottom">Thermo Fisher Scientific, USA</td><td align="left" valign="bottom">11131D</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Ficoll-Paque Plus</td><td align="left" valign="bottom">GE Healthcare, USA, Chicago, Illinois</td><td align="left" valign="bottom">GE17-1440-03</td><td align="left" valign="bottom">For PBMC isolation</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SepMate-50 tubes</td><td align="left" valign="bottom">StemCell Technologies, Canada</td><td align="left" valign="bottom">86450</td><td align="left" valign="bottom">For PBMC isolation</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-CD14 MicroBeads</td><td align="left" valign="bottom">Miltenyi Biotec, Germany</td><td align="left" valign="bottom">130-050-201</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">X-Vivo-15 medium</td><td align="left" valign="bottom">Lonza, Switzerland</td><td align="left" valign="bottom">BE02-060F</td><td align="left" valign="bottom">Cell culture medium for dendritic cells</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">IL-4</td><td align="left" valign="bottom">PeproTech, Germany</td><td align="left" valign="bottom">200–04</td><td align="char" char="." valign="bottom">400 IU/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">GM-CSF</td><td align="left" valign="bottom">PeproTech, Germany</td><td align="left" valign="bottom">300–03</td><td align="char" char="." valign="bottom">800 IU/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">PepTivator Melan-A/MART-1</td><td align="left" valign="bottom">Miltenyi Biotec, Germany</td><td align="left" valign="bottom">130-094-597</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">PepTivator gp100/Pmel</td><td align="left" valign="bottom">Miltenyi Biotec, Germany</td><td align="left" valign="bottom">130-094-449</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">PepTivator MAGE-A3</td><td align="left" valign="bottom">Miltenyi Biotec, Germany</td><td align="left" valign="bottom">130-095-384</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Prostaglandin E<sub>2</sub></td><td align="left" valign="bottom">Sigma-Aldrich, USA, St. Louis, Missouri</td><td align="left" valign="bottom">P0409</td><td align="left" valign="bottom">1 µg/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">IL-1β</td><td align="left" valign="bottom">PeproTech, Germany</td><td align="left" valign="bottom">200-01B</td><td align="char" char="." valign="bottom">10 ng/mL</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">TNF-α</td><td align="left" valign="bottom">PeproTech, Germany</td><td align="left" valign="bottom">300–01A</td><td align="char" char="." valign="bottom">25 ng/mL</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">AIM-V serum-free medium</td><td align="left" valign="bottom">Gibco, USA, Waltham, Massachusetts</td><td align="left" valign="bottom">12055–091</td><td align="left" valign="bottom">Serum-free cell culture medium</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal CD4-BV510 (RPA-T4)</td><td align="left" valign="bottom">BioLegend, Germany</td><td align="left" valign="bottom">cat 300546</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal CD8-Alexa-647 (SK1)</td><td align="left" valign="bottom">BioLegend, Germany</td><td align="left" valign="bottom">cat 344726</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal CD127-APC-Cy7 (IL-7Rα, A019D5)</td><td align="left" valign="bottom">BioLegend, Germany</td><td align="left" valign="bottom">351348</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal CD25-PE (IL-2Rα)</td><td align="left" valign="bottom">Beckman Coulter, USA, Brea, California</td><td align="left" valign="bottom">A07774</td><td align="left" valign="bottom">FACS, flow cytometry, 10 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal CD39-FITC (eBioA1)</td><td align="left" valign="bottom">eBioscience, USA, Santa Clara, California</td><td align="left" valign="bottom">11-0399-42</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal CD137-PE (4B4-1)</td><td align="left" valign="bottom">BioLegend, Germany</td><td align="left" valign="bottom">309804</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal СD25-APC (BC96)</td><td align="left" valign="bottom">BioLegend, Germany</td><td align="left" valign="bottom">302610</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonalPD-1-BV421 (CD279, EH12.2H7)</td><td align="left" valign="bottom">BioLegend, Germany</td><td align="left" valign="bottom">329920</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal CD127-Alexa488 (A019D5)</td><td align="left" valign="bottom">BioLegend, Germany</td><td align="left" valign="bottom">351314</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal CD8-BV421 (SK1)</td><td align="left" valign="bottom">BioLegend, Germany</td><td align="left" valign="bottom">344748</td><td align="left" valign="bottom">FACS, flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-FoxP3-PE (236 A/E7)</td><td align="left" valign="bottom">BD Biosciences, USA, Franklin Lakes, New Jersey</td><td align="left" valign="bottom">560852</td><td align="left" valign="bottom">Flow cytometry, 5 µL/test</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TRIzol reagent</td><td align="left" valign="bottom">Invitrogen, USA, Carlsbad, California</td><td align="left" valign="bottom">15596026</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy mini kit</td><td align="left" valign="bottom">Qiagen, The Netherlands</td><td align="left" valign="bottom">74104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Qubit RNA HS Assay Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific, USA, Waltham, Massachusetts</td><td align="left" valign="bottom">Q32855</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Human RNA TCR Multiplex kit</td><td align="left" valign="bottom">MiLaboratories Inc, USA, Sunnyvale, California</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Patients</title><p>All clinical samples were acquired from the NN Blokhin National Medical Research Center of Oncology in accordance with protocol MoleMed-0921, approved by the ethical committee on January 30, 2020. All patients involved in the study were diagnosed with metastatic melanoma and signed an informed consent prior to collection of their biomaterial. Most experiments were performed on freshly resected metastatic lymph nodes obtained during surgery. Genotyping for BRAF<sup>V600E</sup> was performed at the NN Blokhin National Medical Research Center of Oncology, Pathomorphology Department. From each patient enrolled in this study, we also obtained 20–30 mL of peripheral blood before the surgery. Patient information is provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-2"><title>Brief TIL culture</title><p>Freshly resected tumor specimens were dissected into fragments measuring 1–3 mm in each dimension. Several fragments were frozen in liquid nitrogen for further cDNA library preparation and HLA typing. Individual fragments were seeded into the wells of a 24-well tissue culture plate with 2 mL of complete T cell cultivation medium (CM) supplemented with 5% heat-inactivated human AB serum (PanBiotech, Germany) and 1000 IU/mL IL-2 (Ronkoleukine, BiotechSpb, Russia). CM consisted of RPMI-1640 (PanEco, Russia), 25 µM/mL HEPES, pH 7.2 (PanEco, Russia), 100 IU/mL penicillin, 100 µg/mL streptomycin, 10 µg/mL gentamicin, 1× non-essential amino acids mix, 1× GlutaMAX, β-mercaptoethanol (0.55 µM) (all from Gibco, Thermo Fisher Scientific, USA, Waltham, Massachusetts), and 110 μg/m sodium pyruvate. On the fourth day of cultivation, TILs were harvested, filtered through a 70 μm mesh, stained with fluorophore-labeled antibodies, and FACS sorted. For the generation of TCR repertoire libraries, T cells were sorted directly into the RLT cell lysis buffer (QIAGEN, The Netherlands) and stored at –80°C until used for RNA isolation. For functional assays, TILs were sorted into 1.5 mL Eppendorf tubes with 0.5 mL RPMI-1640. Live-sorted T cells were seeded into wells of 96-well cell culture plate at 10<sup>6</sup> cells/mL in CM and cultured for at least 5 days. Here, CM was supplemented with 1000 IU/mL IL-2, 50 ng/mL IL-21 (SCI-STORE, Russia), 20 μg/mL nivolumab (Bristol-Myers Squibb, USA, New York City, New York), and 10% autologous patient-derived serum. Half of the media was replaced three times a week. One day before the functional assays, all the media was replaced with fresh CM without interleukins or nivolumab.</p></sec><sec id="s4-3"><title>Expansion of bulk TILs</title><p>Fragments of tumor specimens from each of four melanoma patients (mp26, -32, -34, and -42) were plated into separate wells of a 24-well tissue culture plate (1 fragment per well, 1 plate per patient) with basic RPMI-1640-based CM and 5% heat-inactivated human AB serum. Bulk TILs were expanded from tumor fragments in the following different conditions (6 wells/condition) for 9 days: (1) IL-2<sub>high</sub> (3000 IU/mL), (2) IL-2<sub>low</sub> (100 IU/mL), (3) IL-21 (25 ng/mL) + IL-2<sub>low</sub>, (4) nivolumab (20 μg/mL) + IL-21 + IL-2<sup>low</sup>, and (5) IFNγ (100 μg/mL) + nivolumab + IL-21 +IL-2<sub>low</sub>. TILs from patient mp26 were cultivated in conditions 1, 3, 4, and 5; TILs from patients mp32, -34, and -42 were cultured in conditions 1–4. Half of the medium was replaced on days 3 and 5 with the same medium as was used for initial plating. On day 9 of cultivation, TILs from each well were counted and lysed in RLT buffer at 5 × 10<sup>5</sup> cells/mL density for preparation of TCR repertoire libraries.</p></sec><sec id="s4-4"><title>Expansion of sorted T cells</title><p>FACS-sorted T cells were expanded using non-specific TCR-dependent stimulation with anti-CD3/CD28 Dynabeads (Thermo Fisher Scientific, USA, Waltham, Massachusetts). Beads were added into the CM on the next day after seeding the cells, with 2 µL of bead solution per 10<sup>5</sup> cells. Sorted TILs were expanded for 2 weeks. Beads were magnetically removed upon achieving desired cell numbers. Before co-cultivation experiments, cells were allowed to ‘rest’ for 1 day in interleukin-free CM supplemented with 10% autologous patient-derived serum (i.e., ‘resting’ medium).</p></sec><sec id="s4-5"><title>PBMC isolation</title><p>Peripheral blood mononuclear cells (PBMCs) were derived from patients’ blood samples using gradient centrifugation with Ficoll-Paque Plus (GE Healthcare). Briefly, 18 mL of whole blood were diluted to 50 mL volume with sterile 1× PBS. Diluted blood was layered over the Ficoll-Paque solution in 50 mL SepMate tubes (StemCell Technologies, Canada), with 25 mL of diluted blood per tube. SepMate tubes were centrifuged for 20 min at 1200× <italic>g</italic> with brake off. Afterward, buffy coats were collected and washed two times with 50 mL of sterile PBS.</p></sec><sec id="s4-6"><title>Monocyte-derived dendritic cells cultivation</title><p>Autologous dendritic cells were generated as described in <xref ref-type="bibr" rid="bib4">Bacher et al., 2016</xref>. Briefly, CD14<sup>+</sup> cells (monocytes) were isolated from patients’ PBMCs with a magnetic enrichment procedure using anti-CD14 MicroBeads (Miltenyi Biotec, Germany). Then, monocytes were seeded into the wells of 24-well tissue culture plates at 5 × 10<sup>5</sup> cells/well. X-Vivo-15 medium (Lonza, Switzerland) with 400 U/mL IL-4 and 800 U/mL GM-CSF was used for the differentiation of monocytes. On the fourth day of cultivation, the medium was renewed, and dendritic cells were loaded with the mix of melanoma TAA peptides (PepTivator Melan-A/MART-1, gp100/Pmel, and MAGE-A3 human; Miltenyi Biotec) at a concentration of 600 nM each. The next day, loaded DCs were matured using 1 µg/mL PGE, 10 ng/mL IL-1β, and 25 ng/mL TNF-α. Following 24 hr of maturation, DCs were harvested and used for co-cultivation with T cells.</p></sec><sec id="s4-7"><title>CD137 antigen-specific activation assay</title><p>FACS-sorted PD1<sup>+</sup>CD39<sup>+</sup> (DP) and non-DP populations after expansion and 2 days ‘rest’ without IL-2 were co-cultured with antigen-loaded autologous DCs at a ratio of 10:1 T cells:DCs. The co-CM consisted of 1:1 CM plus AIM-V serum-free medium (Gibco, USA, Waltham, Massachusetts) supplemented with 50 ng/mL IL-21. Both CD137<sup>high</sup> and CD137<sup>low</sup> T cells were lysed with RLT buffer for further RNA isolation and TCR library construction. The frequency of CD137<sup>high</sup> cells was measured for both CD4<sup>+</sup> and CD8<sup>+</sup> TILs. Antigen-specific activation was measured as a ratio of CD137<sup>high</sup> T cell frequencies in TILs co-cultured with antigen-loaded vs. unloaded DCs.</p></sec><sec id="s4-8"><title>Flow cytometry</title><p>For FACS of PD1<sup>+</sup>CD39<sup>+</sup> TIL subpopulations, cells were stained with the following antibodies: CD4-BV510 (RPA-T4), CD8-Alexa-647 (SK1), CD127-APC-Cy7 (IL-7Rα, A019D5), PD-1-BV421 (CD279, EH12.2H7) (BioLegend, Germany), CD25-PE (IL-2Rα, Beckman Coulter, USA, Brea, California), CD39-FITC (eBioA1) (eBioscience, USA, Santa Clara, California). Briefly, cells were pelleted, resuspended in the staining solution with fluorescent antibodies, and incubated for 1 hr at 4°C in the dark. Next, the cells were washed and resuspended in PBS at an approximate density of 5 × 10<sup>6</sup> cells/mL. T cells of interest were sorted on a FACS Aria III (BD Biosciences, USA, Franklin Lakes, New Jersey ). Data analysis was performed with FlowJo software (FlowJo, LLC, FlowJo, USA, Ashland, Oregon). To avoid antigen-specific T<sub>reg</sub>-dependent T cell suppression in further functional assays, we identified T<sub>reg</sub>s as CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>-</sup> cells (<xref ref-type="bibr" rid="bib65">Yu et al., 2012</xref>) and sorted them separately. For functional assays, we sorted T cells into CD39<sup>+</sup> PD-1<sup>+</sup> DP and non-DP (CD39 or PD-1 single-positive and double-negative) subpopulations, with CD4<sup>+</sup> and CD8<sup>+</sup> cells together. For TCR library construction, CD4<sup>+</sup> DP and CD8<sup>+</sup> DP cells, as well as corresponding non-DP populations, were sorted separately in order to evaluate individual properties of their TCR repertoires. For the CD137 activation assay, T cells were stained with fluorescently labeled CD4-BV510 (RPA-T4), CD8-Alexa-647 (SK1), CD137-PE (4B4-1) (BioLegend, Germany) antibodies.</p></sec><sec id="s4-9"><title>Nuclear staining for FoxP3</title><p>First, T cells were stained for surface markers with CD4-BV510 (RPA-T4), CD25-APC (BC96), CD127-Alexa488 (A019D5) (BioLegend, Germany) for 30 min at 4°C in the dark. TILs from patient mp41 were also stained with CD8-BV421 (SK1, BioLegend, Germany) to estimate the CD8/CD4 ratio in various cultivation conditions. Next, the cells were washed and resuspended and processed with the eBioscience Intracellular Fixation &amp; Permeabilization Buffer Set according to manufacturer’s instructions with minor alterations. Briefly, stained cells were fixed with Fixation Reagent for 45 min at 4°C in the dark. Then, the fixed cells were washed three times in 1 mL of Permeabilization Reagent, resuspended in 50 µL of Permeabilization Reagent and blocked for 15 min in 2% human serum. Next, cells were stained with 2 µL of anti-FoxP3-PE (236 A/E7) (BD Biosciences, USA, Franklin Lakes, New Jersey) for 1 hr in Permeabilization buffer at 4°C in the dark, washed, and analyzed with a Navios flow cytometer (Beckman Coulter, USA, Brea, California). Finally, the fraction of T<sub>reg</sub>s (CD4<sup>+</sup> CD25<sup>high</sup> CD127<sup>low</sup> FoxP3<sup>high</sup>) out of total CD4<sup>+</sup> T cells was determined.</p></sec><sec id="s4-10"><title>HLA typing</title><p>For patients mp39, mp41, mp42, and mp44, we have only checked for the presence of HLA-A*02. Aliquots of PBMCs or TILs from these patients were stained with anti-HLA-A*02-PE (BD7.2) (BD Biosciences, USA, Franklin Lakes, New Jersey) antibody and analyzed with a Navios flow cytometer. Other patients (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) were HLA typed using NGS at the Center for Precision Genome Editing and Genetic Technologies for Biomedicine (Moscow). For mp26, the following HLA alleles were identified: A*02:01, A*26:01, B*27:05, B*73:01, C*02:02, C*15:05.</p></sec><sec id="s4-11"><title>RNA isolation and TCR library preparation</title><p>RNA from fresh-frozen tumor fragments was isolated using TRIzol reagent (Invitrogen). RNA from RLT-lysed cells was extracted using the RNeasy mini kit (Qiagen) according to the manufacturer’s protocol. RNA concentration was measured with the Qubit RNA HS Assay Kit (Thermo Fisher Scientific, USA, Waltham, Massachusetts). No more than 500 ng of total RNA was used for cDNA synthesis. cDNA libraries were generated using the Human RNA TCR Multiplex kit (MiLaboratories), according to the manufacturer’s protocol. We aimed to achieve coverage of 20 paired-end reads per cell for sorted and cultivated TIL populations, and approximately 2 × 10<sup>6</sup> reads per tumor sample fragment. Sequencing was performed using the Illumina NextSeq platform (2 × 150 bp read length).</p></sec><sec id="s4-12"><title>Analysis of TCR repertoires sequencing data</title><p>TCRseq data was analyzed with MiXCR software (MiLaboratories) in order to extract TCRβ CDR3 clonotypes. VDJtools software was used for processing of MiXCR output TCR repertoire data, calculation of TCR repertoire diversity, and pre-processing of TCR repertoires (i.e., pooling of joined TCR repertoires and down-sampling of TCR repertoires) (<xref ref-type="bibr" rid="bib54">Shugay et al., 2015</xref>).</p></sec><sec id="s4-13"><title>Cluster analysis of TIL TCRβ repertoires</title><p>This analysis was performed using the ALICE algorithm (<xref ref-type="bibr" rid="bib40">Pogorelyy et al., 2019</xref>). We selected clonotypes with read count &gt;1 (removed singletons) to exclude undercorrected erroneous TCR variants that could potentially create false neighbors of abundant clonotypes, distorting the ALICE hit identification process. Briefly, TCRβ repertoire data files were converted into VDJtools tabular format. For each repertoire, we selected columns with amino acid CDR3 sequence, TRBV, TRBJ, clonotype frequency, and read count. These pre-processed TCR repertoire tables were used as an input for the ALICE algorithm. P<sub>gen</sub> of amino acid sequences was estimated using Monte Carlo simulation. For each VJ pair, 5 million TCR sequences were simulated, and 20 iterations of the algorithm were performed. Based on P<sub>gen</sub>, ALICE infers the number of highly similar CDR3 sequences (up to 1 amino acid mismatch) for each clonotype. Under the expectation that antigen-driven clonal selection doesn’t occur, TCRs with high probability of generation are expected to have a high number of neighbors, while for low-probability TCRs there should be low number or no neighbors. Based on this assumption, clonotypes with significantly higher numbers of neighbors than expected from the recombination model (Benjamini-Hochberg-adjusted p <italic>&lt;</italic> 0.001) are expected to have come through convergent antigen-specific selection and expansion. The algorithm output is formed as a list of these significant results referred to as ‘ALICE hits’.</p><p>The number of ALICE hits strongly depends on the initial variability of the TCR repertoire (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1d</xref>). To account for this, ‘Normalized ALICE hits’ metric was calculated by dividing the number of ALICE hits by the number of clonotypes in initial input. ALICE code can be found at <ext-link ext-link-type="uri" xlink:href="https://github.com/pogorely/ALICE">https://github.com/pogorely/ALICE</ext-link> (<xref ref-type="bibr" rid="bib39">Pogorelyy and Green, 2019</xref>).</p><p>To visualize the resultant clusters of convergently selected TCRs, we used the igraph function (<xref ref-type="bibr" rid="bib12">Csardi, 2005</xref>). This function utilizes the de Bruijn graph method to calculate the distance between amino acid sequences of CDR3 regions. It creates a graph file in GML format where each node represents an individual TCR clonotype and the distance between nodes is proportional to the difference between CDR3 amino acid sequences. Edges connected nodes representing TCR clonotypes with Hamming distance ≤1. Graphs were visualized using Gephi 0.9.2 network analysis platform (<xref ref-type="bibr" rid="bib9">Bosler et al., 2009</xref>). The size of the node represents the frequency of the corresponding TCR clonotype. Upon construction of composite graphs including clonotypes from multiple TCR repertoires, identical clonotypes from different TCR repertoires were displayed by separate nodes.</p></sec><sec id="s4-14"><title>Matching cluster-related TCR clonotypes to VDJdb</title><p>We annotated TCR repertoire data using the VDJdb database of TCR with known specificity (<xref ref-type="bibr" rid="bib55">Shugay et al., 2018</xref>). We assumed that TCRs of interest had the same specificity as TCRs from the database if: (1) CDR3 regions of compared TCRs differed no more than by one central amino acid substitution, (2) substituted amino acids belonged to the same group based on their R properties (polar, aliphatic, aromatic, positively/negatively charged), and (3) HLA restriction of TCR clonotypes from the database matched one of the patient’s HLA alleles, if known.</p><p>TCR clusters consisting predominantly of TAA-specific clonotypes, but not clonotypes of other specificities, were considered TAA-specific as a whole. VDJdb-unmatched members of the TAA-specific clusters were deemed to possess the same specificity as the whole cluster based on structural similarity to VDJdb-matched clonotypes and were included in the subsequent analysis.</p></sec><sec id="s4-15"><title>Analysis of differentially expanded clonotypes with edgeR software</title><p>We used a statistical approach implemented in the edgeR (<xref ref-type="bibr" rid="bib45">Robinson et al., 2010</xref>) package to identify TCRβ clonotypes that were significantly expanded in bulk TILs of patients mp26 and mp34. We implemented edgeR for comparison of TCR repertoires of TILs cultivated in experimental conditions 2–4 (described above) and TILs expanded in IL-2<sub>high</sub> conditions. Six and four biological replicate samples of each cultivation setting were used for the analysis of TCR repertoires from mp26 and mp34, respectively. TCR clonotypes were deemed expanded if the false discovery rate adjusted p value was &lt; 0.01 and the log<sub>2</sub> fold-change was &gt;1.</p></sec><sec id="s4-16"><title>Statistical analysis</title><p>Statistical analysis was performed using GraphPad Prism 8.0 (GraphPad Software Inc, USA, San Diego, California). All data was reported as mean ± SD. The Shapiro-Wilk test was used for normality estimation in all cases. Names of statistical tests and numbers of biological replicas in each comparison group are provided in the figure legends.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Resources, Writing – original draft</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Project administration, Writing – original draft</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Funding acquisition</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Funding acquisition, Investigation, Methodology, Resources, Supervision, Visualization, Writing – original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Methodology, Supervision, Visualization, Writing – original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All clinical samples were acquired from the N.N. Blokhin National Medical Research Center of Oncology in accordance with protocol MoleMed-0921, approved by the ethical committee on 30 Jan 2020. All patients involved in the study were diagnosed with metastatic melanoma and signed an informed consent prior to collection of their biomaterial.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Patients and clinical characteristics.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-77274-supp1-v3.docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-77274-mdarchecklist1-v3.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>TCR repertoires have been deposited on: <ext-link ext-link-type="uri" xlink:href="https://figshare.com/projects/Pinpointing_the_tumor-specific_T-cells_via_TCR_clusters/125284">https://figshare.com/projects/Pinpointing_the_tumor-specific_T-cells_via_TCR_clusters/125284</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Goncharov</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Pinpointing the tumor-specific T-cells via TCR clusters</data-title><source>figshare</source><pub-id pub-id-type="accession" xlink:href="https://figshare.com/projects/Pinpointing_the_tumor-specific_T-cells_via_TCR_clusters/125284">125284</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine (Moscow) for the genetic research methods, and personally V Cheranev and D Korostin for HLA typing of patient tumor material. We thank Valeria V Kriukova for the help with data analysis. We thank Skoltech Genomics Core Facility for performing high-throughput sequencing of mp41 libraries (Skoltech Life Sciences Program grant for the use of shared facilities, received by M Goncharov). We are grateful to Michael Eisenstein for his valuable help in editing the manuscript. Funding: Supported by the grant of the Ministry of Science and Higher Education of the Russian Federation № 075-15-2020-807.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adeegbe</surname><given-names>DO</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Natural and induced T regulatory cells in cancer</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>190</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00190</pub-id><pub-id pub-id-type="pmid">23874336</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Lemaitre</surname><given-names>F</given-names></name><name><surname>Law</surname><given-names>HKW</given-names></name><name><surname>Hasan</surname><given-names>M</given-names></name><name><surname>Albert</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies</article-title><source>Blood</source><volume>115</volume><fpage>3718</fpage><lpage>3725</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-251124</pub-id><pub-id pub-id-type="pmid">20200354</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allard</surname><given-names>E-L</given-names></name><name><surname>Hardy</surname><given-names>M-P</given-names></name><name><surname>Leignadier</surname><given-names>J</given-names></name><name><surname>Marquis</surname><given-names>M</given-names></name><name><surname>Rooney</surname><given-names>J</given-names></name><name><surname>Lehoux</surname><given-names>D</given-names></name><name><surname>Labrecque</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Overexpression of IL-21 promotes massive CD8+ memory T cell accumulation</article-title><source>European Journal of Immunology</source><volume>37</volume><fpage>3069</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1002/eji.200637017</pub-id><pub-id pub-id-type="pmid">17918202</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Heinrich</surname><given-names>F</given-names></name><name><surname>Stervbo</surname><given-names>U</given-names></name><name><surname>Nienen</surname><given-names>M</given-names></name><name><surname>Vahldieck</surname><given-names>M</given-names></name><name><surname>Iwert</surname><given-names>C</given-names></name><name><surname>Vogt</surname><given-names>K</given-names></name><name><surname>Kollet</surname><given-names>J</given-names></name><name><surname>Babel</surname><given-names>N</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><name><surname>Schwarz</surname><given-names>C</given-names></name><name><surname>Bereswill</surname><given-names>S</given-names></name><name><surname>Heimesaat</surname><given-names>MM</given-names></name><name><surname>Heine</surname><given-names>G</given-names></name><name><surname>Gadermaier</surname><given-names>G</given-names></name><name><surname>Asam</surname><given-names>C</given-names></name><name><surname>Assenmacher</surname><given-names>M</given-names></name><name><surname>Kniemeyer</surname><given-names>O</given-names></name><name><surname>Brakhage</surname><given-names>AA</given-names></name><name><surname>Ferreira</surname><given-names>F</given-names></name><name><surname>Wallner</surname><given-names>M</given-names></name><name><surname>Worm</surname><given-names>M</given-names></name><name><surname>Scheffold</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans</article-title><source>Cell</source><volume>167</volume><fpage>1067</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.050</pub-id><pub-id pub-id-type="pmid">27773482</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagaev</surname><given-names>DV</given-names></name><name><surname>Vroomans</surname><given-names>RMA</given-names></name><name><surname>Samir</surname><given-names>J</given-names></name><name><surname>Stervbo</surname><given-names>U</given-names></name><name><surname>Rius</surname><given-names>C</given-names></name><name><surname>Dolton</surname><given-names>G</given-names></name><name><surname>Greenshields-Watson</surname><given-names>A</given-names></name><name><surname>Attaf</surname><given-names>M</given-names></name><name><surname>Egorov</surname><given-names>ES</given-names></name><name><surname>Zvyagin</surname><given-names>IV</given-names></name><name><surname>Babel</surname><given-names>N</given-names></name><name><surname>Cole</surname><given-names>DK</given-names></name><name><surname>Godkin</surname><given-names>AJ</given-names></name><name><surname>Sewell</surname><given-names>AK</given-names></name><name><surname>Kesmir</surname><given-names>C</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Shugay</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D1057</fpage><lpage>D1062</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz874</pub-id><pub-id pub-id-type="pmid">31588507</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balança</surname><given-names>C-C</given-names></name><name><surname>Salvioni</surname><given-names>A</given-names></name><name><surname>Scarlata</surname><given-names>C-M</given-names></name><name><surname>Michelas</surname><given-names>M</given-names></name><name><surname>Martinez-Gomez</surname><given-names>C</given-names></name><name><surname>Gomez-Roca</surname><given-names>C</given-names></name><name><surname>Sarradin</surname><given-names>V</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name><name><surname>Pont</surname><given-names>F</given-names></name><name><surname>Ferron</surname><given-names>G</given-names></name><name><surname>Gladieff</surname><given-names>L</given-names></name><name><surname>Vergez</surname><given-names>S</given-names></name><name><surname>Dupret-Bories</surname><given-names>A</given-names></name><name><surname>Mery</surname><given-names>E</given-names></name><name><surname>Rochaix</surname><given-names>P</given-names></name><name><surname>Fournié</surname><given-names>J-J</given-names></name><name><surname>Delord</surname><given-names>J-P</given-names></name><name><surname>Devaud</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Ayyoub</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>142513</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.142513</pub-id><pub-id pub-id-type="pmid">33332284</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>EW</given-names></name><name><surname>Kersten</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Fearon</surname><given-names>DF</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name><name><surname>Ostrand-Rosenberg</surname><given-names>S</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Howcroft</surname><given-names>TK</given-names></name><name><surname>Woodhouse</surname><given-names>EC</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Understanding the tumor immune microenvironment (TIME) for effective therapy</article-title><source>Nature Medicine</source><volume>24</volume><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0014-x</pub-id><pub-id pub-id-type="pmid">29686425</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>B</given-names></name><name><surname>Vigneron</surname><given-names>J</given-names></name><name><surname>Levacher</surname><given-names>B</given-names></name><name><surname>Vazquez</surname><given-names>T</given-names></name><name><surname>Pitoiset</surname><given-names>F</given-names></name><name><surname>Brimaud</surname><given-names>F</given-names></name><name><surname>Churlaud</surname><given-names>G</given-names></name><name><surname>Klatzmann</surname><given-names>D</given-names></name><name><surname>Bellier</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Low-Dose IL-2 Induces Regulatory T Cell-Mediated Control of Experimental Food Allergy</article-title><source>Journal of Immunology (Baltimore, Md)</source><volume>197</volume><fpage>188</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501271</pub-id><pub-id pub-id-type="pmid">27259854</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosler</surname><given-names>O</given-names></name><name><surname>Girardet</surname><given-names>C</given-names></name><name><surname>Sage-Ciocca</surname><given-names>D</given-names></name><name><surname>Jacomy</surname><given-names>H</given-names></name><name><surname>François-Bellan</surname><given-names>A-M</given-names></name><name><surname>Becquet</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mechanisms of structural plasticity associated with photic synchronization of the circadian clock within the suprachiasmatic nucleus</article-title><source>Journal de La Societe de Biologie</source><volume>203</volume><fpage>49</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1051/jbio:2009004</pub-id><pub-id pub-id-type="pmid">19358811</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrette</surname><given-names>F</given-names></name><name><surname>Surh</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis</article-title><source>Seminars in Immunology</source><volume>24</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2012.04.010</pub-id><pub-id pub-id-type="pmid">22551764</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapuis</surname><given-names>AG</given-names></name><name><surname>Roberts</surname><given-names>IM</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Margolin</surname><given-names>KA</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Sloan</surname><given-names>HL</given-names></name><name><surname>Lai</surname><given-names>IP</given-names></name><name><surname>Farrar</surname><given-names>EA</given-names></name><name><surname>Wagener</surname><given-names>F</given-names></name><name><surname>Shibuya</surname><given-names>KC</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Yee</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>3787</fpage><lpage>3795</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.65.5142</pub-id><pub-id pub-id-type="pmid">27269940</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csardi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The igraph software package for complex network research</article-title><source>InterJournal, Complex Systems</source><volume>15</volume><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><name><surname>Evdemon-Hogan</surname><given-names>M</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Burow</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><name><surname>Lackner</surname><given-names>A</given-names></name><name><surname>Disis</surname><given-names>ML</given-names></name><name><surname>Knutson</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</article-title><source>Nature Medicine</source><volume>10</volume><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1038/nm1093</pub-id><pub-id pub-id-type="pmid">15322536</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname><given-names>P</given-names></name><name><surname>Fiore-Gartland</surname><given-names>AJ</given-names></name><name><surname>Hertz</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>GC</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Souquette</surname><given-names>A</given-names></name><name><surname>Crawford</surname><given-names>JC</given-names></name><name><surname>Clemens</surname><given-names>EB</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>La Gruta</surname><given-names>NL</given-names></name><name><surname>Bradley</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Quantifiable predictive features define epitope-specific T cell receptor repertoires</article-title><source>Nature</source><volume>547</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nature22383</pub-id><pub-id pub-id-type="pmid">28636592</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Shelton</surname><given-names>TE</given-names></name><name><surname>Even</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients</article-title><source>Journal of Immunotherapy (Hagerstown, Md</source><volume>26</volume><fpage>332</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1097/00002371-200307000-00005</pub-id><pub-id pub-id-type="pmid">12843795</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duhen</surname><given-names>T</given-names></name><name><surname>Duhen</surname><given-names>R</given-names></name><name><surname>Montler</surname><given-names>R</given-names></name><name><surname>Moses</surname><given-names>J</given-names></name><name><surname>Moudgil</surname><given-names>T</given-names></name><name><surname>de Miranda</surname><given-names>NF</given-names></name><name><surname>Goodall</surname><given-names>CP</given-names></name><name><surname>Blair</surname><given-names>TC</given-names></name><name><surname>Fox</surname><given-names>BA</given-names></name><name><surname>McDermott</surname><given-names>JE</given-names></name><name><surname>Chang</surname><given-names>S-C</given-names></name><name><surname>Grunkemeier</surname><given-names>G</given-names></name><name><surname>Leidner</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>RB</given-names></name><name><surname>Weinberg</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2724</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05072-0</pub-id><pub-id pub-id-type="pmid">30006565</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elhanati</surname><given-names>Y</given-names></name><name><surname>Sethna</surname><given-names>Z</given-names></name><name><surname>Callan</surname><given-names>CG</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Predicting the spectrum of TCR repertoire sharing with a data-driven model of recombination</article-title><source>Immunological Reviews</source><volume>284</volume><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/imr.12665</pub-id><pub-id pub-id-type="pmid">29944757</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari-Lacraz</surname><given-names>S</given-names></name><name><surname>Chicheportiche</surname><given-names>R</given-names></name><name><surname>Schneiter</surname><given-names>G</given-names></name><name><surname>Molnarfi</surname><given-names>N</given-names></name><name><surname>Villard</surname><given-names>J</given-names></name><name><surname>Dayer</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes</article-title><source>International Immunology</source><volume>20</volume><fpage>1009</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxn059</pub-id><pub-id pub-id-type="pmid">18556671</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname><given-names>J</given-names></name><name><surname>Ramanathan</surname><given-names>S</given-names></name><name><surname>Leblanc</surname><given-names>C</given-names></name><name><surname>Cloutier</surname><given-names>A</given-names></name><name><surname>McDonald</surname><given-names>PP</given-names></name><name><surname>Ilangumaran</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>180</volume><fpage>7958</fpage><lpage>7968</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.12.7958</pub-id><pub-id pub-id-type="pmid">18523259</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glanville</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Nau</surname><given-names>A</given-names></name><name><surname>Hatton</surname><given-names>O</given-names></name><name><surname>Wagar</surname><given-names>LE</given-names></name><name><surname>Rubelt</surname><given-names>F</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Krams</surname><given-names>SM</given-names></name><name><surname>Pettus</surname><given-names>C</given-names></name><name><surname>Haas</surname><given-names>N</given-names></name><name><surname>Arlehamn</surname><given-names>CSL</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Boyd</surname><given-names>SD</given-names></name><name><surname>Scriba</surname><given-names>TJ</given-names></name><name><surname>Martinez</surname><given-names>OM</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identifying specificity groups in the T cell receptor repertoire</article-title><source>Nature</source><volume>547</volume><fpage>94</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nature22976</pub-id><pub-id pub-id-type="pmid">28636589</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grivennikov</surname><given-names>SI</given-names></name><name><surname>Greten</surname><given-names>FR</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Immunity, inflammation, and cancer</article-title><source>Cell</source><volume>140</volume><fpage>883</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.01.025</pub-id><pub-id pub-id-type="pmid">20303878</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gros</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>YF</given-names></name><name><surname>Turcotte</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>E</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Mixon</surname><given-names>A</given-names></name><name><surname>Farid</surname><given-names>S</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Hanada</surname><given-names>KI</given-names></name><name><surname>Almeida</surname><given-names>JR</given-names></name><name><surname>Darko</surname><given-names>S</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PD-1 identifies the patient-specific CD8</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>2246</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1172/JCI73639</pub-id><pub-id pub-id-type="pmid">24667641</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inozume</surname><given-names>T</given-names></name><name><surname>Hanada</surname><given-names>K-I</given-names></name><name><surname>Wang</surname><given-names>QJ</given-names></name><name><surname>Ahmadzadeh</surname><given-names>M</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells</article-title><source>Journal of Immunotherapy (Hagerstown, Md</source><volume>33</volume><fpage>956</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3181fad2b0</pub-id><pub-id pub-id-type="pmid">20948441</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelderman</surname><given-names>S</given-names></name><name><surname>Heemskerk</surname><given-names>B</given-names></name><name><surname>Fanchi</surname><given-names>L</given-names></name><name><surname>Philips</surname><given-names>D</given-names></name><name><surname>Toebes</surname><given-names>M</given-names></name><name><surname>Kvistborg</surname><given-names>P</given-names></name><name><surname>van Buuren</surname><given-names>MM</given-names></name><name><surname>van Rooij</surname><given-names>N</given-names></name><name><surname>Michels</surname><given-names>S</given-names></name><name><surname>Germeroth</surname><given-names>L</given-names></name><name><surname>Haanen</surname><given-names>JBAG</given-names></name><name><surname>Schumacher</surname><given-names>NM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy</article-title><source>European Journal of Immunology</source><volume>46</volume><fpage>1351</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1002/eji.201545849</pub-id><pub-id pub-id-type="pmid">27005018</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klebanoff</surname><given-names>CA</given-names></name><name><surname>Khong</surname><given-names>HT</given-names></name><name><surname>Antony</surname><given-names>PA</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy</article-title><source>Trends in Immunology</source><volume>26</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.it.2004.12.003</pub-id><pub-id pub-id-type="pmid">15668127</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortekaas</surname><given-names>KE</given-names></name><name><surname>Santegoets</surname><given-names>SJ</given-names></name><name><surname>Sturm</surname><given-names>G</given-names></name><name><surname>Ehsan</surname><given-names>I</given-names></name><name><surname>van Egmond</surname><given-names>SL</given-names></name><name><surname>Finotello</surname><given-names>F</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name><name><surname>Welters</surname><given-names>MJP</given-names></name><name><surname>van Poelgeest</surname><given-names>MIE</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CD39 Identifies the CD4<sup>+</sup> Tumor-Specific T-cell Population in Human Cancer</article-title><source>Cancer Immunology Research</source><volume>8</volume><fpage>1311</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-20-0270</pub-id><pub-id pub-id-type="pmid">32759363</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kvistborg</surname><given-names>P</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Enhancing responses to cancer immunotherapy</article-title><source>Science (New York, N.Y.)</source><volume>359</volume><fpage>516</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1126/science.aar6574</pub-id><pub-id pub-id-type="pmid">29420276</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leko</surname><given-names>V</given-names></name><name><surname>McDuffie</surname><given-names>LA</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Gartner</surname><given-names>JJ</given-names></name><name><surname>Prickett</surname><given-names>TD</given-names></name><name><surname>Apolo</surname><given-names>AB</given-names></name><name><surname>Agarwal</surname><given-names>PK</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Lu</surname><given-names>YC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer</article-title><source>Journal of Immunology (Baltimore, Md)</source><volume>202</volume><fpage>3458</fpage><lpage>3467</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1801022</pub-id><pub-id pub-id-type="pmid">31036766</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Kostareli</surname><given-names>E</given-names></name><name><surname>Suffner</surname><given-names>J</given-names></name><name><surname>Garbi</surname><given-names>N</given-names></name><name><surname>Hämmerling</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Efficient Treg depletion induces T-cell infiltration and rejection of large tumors</article-title><source>European Journal of Immunology</source><volume>40</volume><fpage>3325</fpage><lpage>3335</lpage><pub-id pub-id-type="doi">10.1002/eji.201041093</pub-id><pub-id pub-id-type="pmid">21072887</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High-dimensional profiling of tumor-infiltrating CD4+T cells in Human cancer: Are they all tumor-specific</article-title><source>The Journal of Immunology</source><volume>204</volume><elocation-id>243</elocation-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melief</surname><given-names>SM</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name><name><surname>Verdegaal</surname><given-names>EME</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma</article-title><source>Cancer Immunology, Immunotherapy</source><volume>66</volume><fpage>913</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1007/s00262-017-1995-x</pub-id><pub-id pub-id-type="pmid">28401257</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moesta</surname><given-names>AK</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting CD39 in cancer</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>739</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0376-4</pub-id><pub-id pub-id-type="pmid">32728220</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Fuertes Marraco</surname><given-names>SA</given-names></name><name><surname>Baumgaertner</surname><given-names>P</given-names></name><name><surname>Bordry</surname><given-names>N</given-names></name><name><surname>Cagnon</surname><given-names>L</given-names></name><name><surname>Donda</surname><given-names>A</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Verdeil</surname><given-names>G</given-names></name><name><surname>Speiser</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients</article-title><source>Frontiers in Immunology</source><volume>7</volume><elocation-id>573</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2016.00573</pub-id><pub-id pub-id-type="pmid">28018343</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kwon</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>T-S</given-names></name><name><surname>Hong</surname><given-names>S-H</given-names></name><name><surname>Kim</surname><given-names>CG</given-names></name><name><surname>Kang</surname><given-names>S-G</given-names></name><name><surname>Moon</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Park</surname><given-names>S-H</given-names></name><name><surname>Chang</surname><given-names>JH</given-names></name><name><surname>Shin</surname><given-names>E-C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8<sup>+</sup> T Cells is Determined by Their Differentiation Status in Glioblastoma</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>2549</fpage><lpage>2559</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2564</pub-id><pub-id pub-id-type="pmid">30659023</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauken</surname><given-names>KE</given-names></name><name><surname>Shahid</surname><given-names>O</given-names></name><name><surname>Lagattuta</surname><given-names>KA</given-names></name><name><surname>Mahuron</surname><given-names>KM</given-names></name><name><surname>Luber</surname><given-names>JM</given-names></name><name><surname>Lowe</surname><given-names>MM</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Delaney</surname><given-names>C</given-names></name><name><surname>Long</surname><given-names>JM</given-names></name><name><surname>Fung</surname><given-names>ME</given-names></name><name><surname>Newcomer</surname><given-names>K</given-names></name><name><surname>Tsai</surname><given-names>KK</given-names></name><name><surname>Chow</surname><given-names>M</given-names></name><name><surname>Guinn</surname><given-names>S</given-names></name><name><surname>Kuchroo</surname><given-names>JR</given-names></name><name><surname>Burke</surname><given-names>KP</given-names></name><name><surname>Schenkel</surname><given-names>JM</given-names></name><name><surname>Rosenblum</surname><given-names>MD</given-names></name><name><surname>Daud</surname><given-names>AI</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20200920</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20200920</pub-id><pub-id pub-id-type="pmid">33651880</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>V</given-names></name><name><surname>Annicchiarico-Petruzzelli</surname><given-names>M</given-names></name><name><surname>Melino</surname><given-names>G</given-names></name><name><surname>Amelio</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The hypoxic tumour microenvironment</article-title><source>Oncogenesis</source><volume>7</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1038/s41389-017-0011-9</pub-id><pub-id pub-id-type="pmid">29362402</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Dunbar</surname><given-names>PR</given-names></name><name><surname>Speiser</surname><given-names>DE</given-names></name><name><surname>Liénard</surname><given-names>D</given-names></name><name><surname>Lejeune</surname><given-names>F</given-names></name><name><surname>Fleischhauer</surname><given-names>K</given-names></name><name><surname>Cerundolo</surname><given-names>V</given-names></name><name><surname>Cerottini</surname><given-names>JC</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in A large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals</article-title><source>The Journal of Experimental Medicine</source><volume>190</volume><fpage>705</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1084/jem.190.5.705</pub-id><pub-id pub-id-type="pmid">10477554</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Minervina</surname><given-names>AA</given-names></name><name><surname>Touzel</surname><given-names>MP</given-names></name><name><surname>Sycheva</surname><given-names>AL</given-names></name><name><surname>Komech</surname><given-names>EA</given-names></name><name><surname>Kovalenko</surname><given-names>EI</given-names></name><name><surname>Karganova</surname><given-names>GG</given-names></name><name><surname>Egorov</surname><given-names>ES</given-names></name><name><surname>Komkov</surname><given-names>AY</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Mamedov</surname><given-names>IZ</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name><name><surname>Lebedev</surname><given-names>YB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Precise tracking of vaccine-responding T cell clones reveals convergent and personalized response in identical twins</article-title><source>PNAS</source><volume>115</volume><fpage>12704</fpage><lpage>12709</lpage><pub-id pub-id-type="doi">10.1073/pnas.1809642115</pub-id><pub-id pub-id-type="pmid">30459272</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Green</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>ALICE: Detecting TCR involved in immune responses from single RepSeq datasets</data-title><version designator="dafd6c2">dafd6c2</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/pogorely/ALICE">https://github.com/pogorely/ALICE</ext-link></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Minervina</surname><given-names>AA</given-names></name><name><surname>Shugay</surname><given-names>M</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Lebedev</surname><given-names>YB</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Detecting T cell receptors involved in immune responses from single repertoire snapshots</article-title><source>PLOS Biology</source><volume>17</volume><elocation-id>e3000314</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000314</pub-id><pub-id pub-id-type="pmid">31194732</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Shugay</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Framework for Annotation of Antigen Specificities in High-Throughput T-Cell Repertoire Sequencing Studies</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2159</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02159</pub-id><pub-id pub-id-type="pmid">31616409</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przybyla</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Roen</surname><given-names>DR</given-names></name><name><surname>Mackiewicz</surname><given-names>A</given-names></name><name><surname>Lehmann</surname><given-names>PV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8 + memory T cells can be detected in healthy humans</article-title><source>Cancer Immunology, Immunotherapy</source><volume>68</volume><fpage>709</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1007/s00262-018-02292-7</pub-id><pub-id pub-id-type="pmid">30783693</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Montagut</surname><given-names>T</given-names></name><name><surname>Andrews</surname><given-names>DM</given-names></name><name><surname>Ihara</surname><given-names>A</given-names></name><name><surname>Pervaiz</surname><given-names>S</given-names></name><name><surname>Pandolfi</surname><given-names>F</given-names></name><name><surname>Van Den Elsen</surname><given-names>PJ</given-names></name><name><surname>Waitkus</surname><given-names>R</given-names></name><name><surname>Boyle</surname><given-names>LA</given-names></name><name><surname>Hishii</surname><given-names>M</given-names></name><name><surname>Kurnick</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1</article-title><source>Clinical and Experimental Immunology</source><volume>119</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01089.x</pub-id><pub-id pub-id-type="pmid">10606959</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>Havel</surname><given-names>JJ</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Desrichard</surname><given-names>A</given-names></name><name><surname>Urba</surname><given-names>WJ</given-names></name><name><surname>Sims</surname><given-names>JS</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Martín-Algarra</surname><given-names>S</given-names></name><name><surname>Mandal</surname><given-names>R</given-names></name><name><surname>Sharfman</surname><given-names>WH</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name><name><surname>Slingluff</surname><given-names>CL</given-names></name><name><surname>Chowell</surname><given-names>D</given-names></name><name><surname>Kendall</surname><given-names>SM</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Kuo</surname><given-names>F</given-names></name><name><surname>Morris</surname><given-names>LGT</given-names></name><name><surname>Sidhom</surname><given-names>JW</given-names></name><name><surname>Schneck</surname><given-names>JP</given-names></name><name><surname>Horak</surname><given-names>CE</given-names></name><name><surname>Weinhold</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab</article-title><source>Cell</source><volume>171</volume><fpage>934</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.028</pub-id><pub-id pub-id-type="pmid">29033130</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics (Oxford, England)</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Dunbar</surname><given-names>PR</given-names></name><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Pittet</surname><given-names>M</given-names></name><name><surname>Ogg</surname><given-names>GS</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name><name><surname>Liénard</surname><given-names>D</given-names></name><name><surname>Cerottini</surname><given-names>JC</given-names></name><name><surname>Cerundolo</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes</article-title><source>The Journal of Experimental Medicine</source><volume>188</volume><fpage>1641</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1084/jem.188.9.1641</pub-id><pub-id pub-id-type="pmid">9802976</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Packard</surname><given-names>BS</given-names></name><name><surname>Aebersold</surname><given-names>PM</given-names></name><name><surname>Solomon</surname><given-names>D</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Toy</surname><given-names>ST</given-names></name><name><surname>Simon</surname><given-names>P</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Seipp</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report</article-title><source>The New England Journal of Medicine</source><volume>319</volume><fpage>1676</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1056/NEJM198812223192527</pub-id><pub-id pub-id-type="pmid">3264384</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Yannelli</surname><given-names>JR</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Schwartzentruber</surname><given-names>DJ</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Parkinson</surname><given-names>DR</given-names></name><name><surname>Seipp</surname><given-names>CA</given-names></name><name><surname>Einhorn</surname><given-names>JH</given-names></name><name><surname>White</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2</article-title><source>Journal of the National Cancer Institute</source><volume>86</volume><fpage>1159</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1093/jnci/86.15.1159</pub-id><pub-id pub-id-type="pmid">8028037</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Adoptive cell transfer as personalized immunotherapy for human cancer</article-title><source>Science (New York, N.Y.)</source><volume>348</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4967</pub-id><pub-id pub-id-type="pmid">25838374</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santegoets</surname><given-names>S</given-names></name><name><surname>Turksma</surname><given-names>AW</given-names></name><name><surname>Suhoski</surname><given-names>MM</given-names></name><name><surname>Stam</surname><given-names>AGM</given-names></name><name><surname>Albelda</surname><given-names>SM</given-names></name><name><surname>Hooijberg</surname><given-names>E</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>van den Eertwegh</surname><given-names>AJM</given-names></name><name><surname>Gerritsen</surname><given-names>WR</given-names></name><name><surname>Powell</surname><given-names>DJ</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>de Gruijl</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells</article-title><source>Journal of Translational Medicine</source><volume>11</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/1479-5876-11-37</pub-id><pub-id pub-id-type="pmid">23402380</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarnaik</surname><given-names>AA</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Khushalani</surname><given-names>NI</given-names></name><name><surname>Lewis</surname><given-names>KD</given-names></name><name><surname>Medina</surname><given-names>T</given-names></name><name><surname>Kluger</surname><given-names>HM</given-names></name><name><surname>Thomas</surname><given-names>SS</given-names></name><name><surname>Domingo-Musibay</surname><given-names>E</given-names></name><name><surname>Pavlick</surname><given-names>AC</given-names></name><name><surname>Whitman</surname><given-names>ED</given-names></name><name><surname>Martin-Algarra</surname><given-names>S</given-names></name><name><surname>Corrie</surname><given-names>P</given-names></name><name><surname>Curti</surname><given-names>BD</given-names></name><name><surname>Oláh</surname><given-names>J</given-names></name><name><surname>Lutzky</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Larkin</surname><given-names>JMG</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Takamura</surname><given-names>T</given-names></name><name><surname>Jagasia</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Chartier</surname><given-names>C</given-names></name><name><surname>Graf Finckenstein</surname><given-names>F</given-names></name><name><surname>Fardis</surname><given-names>M</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Chesney</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma</article-title><source>Journal of Clinical Oncology</source><volume>39</volume><fpage>2656</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.00612</pub-id><pub-id pub-id-type="pmid">33979178</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seliger</surname><given-names>B</given-names></name><name><surname>Maeurer</surname><given-names>MJ</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Antigen-processing machinery breakdown and tumor growth</article-title><source>Immunology Today</source><volume>21</volume><fpage>455</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/s0167-5699(00)01692-3</pub-id><pub-id pub-id-type="pmid">10953098</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seliktar-Ofir</surname><given-names>S</given-names></name><name><surname>Merhavi-Shoham</surname><given-names>E</given-names></name><name><surname>Itzhaki</surname><given-names>O</given-names></name><name><surname>Yunger</surname><given-names>S</given-names></name><name><surname>Markel</surname><given-names>G</given-names></name><name><surname>Schachter</surname><given-names>J</given-names></name><name><surname>Besser</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>1211</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.01211</pub-id><pub-id pub-id-type="pmid">29067023</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shugay</surname><given-names>M</given-names></name><name><surname>Bagaev</surname><given-names>DV</given-names></name><name><surname>Turchaninova</surname><given-names>MA</given-names></name><name><surname>Bolotin</surname><given-names>DA</given-names></name><name><surname>Britanova</surname><given-names>OV</given-names></name><name><surname>Putintseva</surname><given-names>EV</given-names></name><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Nazarov</surname><given-names>VI</given-names></name><name><surname>Zvyagin</surname><given-names>IV</given-names></name><name><surname>Kirgizova</surname><given-names>VI</given-names></name><name><surname>Kirgizov</surname><given-names>KI</given-names></name><name><surname>Skorobogatova</surname><given-names>EV</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004503</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004503</pub-id><pub-id pub-id-type="pmid">26606115</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shugay</surname><given-names>M</given-names></name><name><surname>Bagaev</surname><given-names>DV</given-names></name><name><surname>Zvyagin</surname><given-names>IV</given-names></name><name><surname>Vroomans</surname><given-names>RM</given-names></name><name><surname>Crawford</surname><given-names>JC</given-names></name><name><surname>Dolton</surname><given-names>G</given-names></name><name><surname>Komech</surname><given-names>EA</given-names></name><name><surname>Sycheva</surname><given-names>AL</given-names></name><name><surname>Koneva</surname><given-names>AE</given-names></name><name><surname>Egorov</surname><given-names>ES</given-names></name><name><surname>Eliseev</surname><given-names>AV</given-names></name><name><surname>Van Dyk</surname><given-names>E</given-names></name><name><surname>Dash</surname><given-names>P</given-names></name><name><surname>Attaf</surname><given-names>M</given-names></name><name><surname>Rius</surname><given-names>C</given-names></name><name><surname>Ladell</surname><given-names>K</given-names></name><name><surname>McLaren</surname><given-names>JE</given-names></name><name><surname>Matthews</surname><given-names>KK</given-names></name><name><surname>Clemens</surname><given-names>EB</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>van Baarle</surname><given-names>D</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>Kesmir</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Sewell</surname><given-names>AK</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>VDJdb: a curated database of T-cell receptor sequences with known antigen specificity</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D419</fpage><lpage>D427</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx760</pub-id><pub-id pub-id-type="pmid">28977646</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoni</surname><given-names>Y</given-names></name><name><surname>Becht</surname><given-names>E</given-names></name><name><surname>Fehlings</surname><given-names>M</given-names></name><name><surname>Loh</surname><given-names>CY</given-names></name><name><surname>Koo</surname><given-names>S-L</given-names></name><name><surname>Teng</surname><given-names>KWW</given-names></name><name><surname>Yeong</surname><given-names>JPS</given-names></name><name><surname>Nahar</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Kared</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Ang</surname><given-names>N</given-names></name><name><surname>Poidinger</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>YY</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name><name><surname>Khng</surname><given-names>AJ</given-names></name><name><surname>Tan</surname><given-names>E</given-names></name><name><surname>Fu</surname><given-names>C</given-names></name><name><surname>Mathew</surname><given-names>R</given-names></name><name><surname>Teo</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>WT</given-names></name><name><surname>Toh</surname><given-names>CK</given-names></name><name><surname>Ong</surname><given-names>B-H</given-names></name><name><surname>Koh</surname><given-names>T</given-names></name><name><surname>Hillmer</surname><given-names>AM</given-names></name><name><surname>Takano</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>TKH</given-names></name><name><surname>Tan</surname><given-names>EH</given-names></name><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>DSW</given-names></name><name><surname>Tan</surname><given-names>IB</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Bystander CD8<sup>+</sup> T cells are abundant and phenotypically distinct in human tumour infiltrates</article-title><source>Nature</source><volume>557</volume><fpage>575</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0130-2</pub-id><pub-id pub-id-type="pmid">29769722</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiess</surname><given-names>PJ</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2</article-title><source>Journal of the National Cancer Institute</source><volume>79</volume><fpage>1067</fpage><lpage>1075</lpage><pub-id pub-id-type="pmid">3500355</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spranger</surname><given-names>S</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity</article-title><source>Nature</source><volume>523</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/nature14404</pub-id><pub-id pub-id-type="pmid">25970248</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thommen</surname><given-names>DS</given-names></name><name><surname>Koelzer</surname><given-names>VH</given-names></name><name><surname>Herzig</surname><given-names>P</given-names></name><name><surname>Roller</surname><given-names>A</given-names></name><name><surname>Trefny</surname><given-names>M</given-names></name><name><surname>Dimeloe</surname><given-names>S</given-names></name><name><surname>Kiialainen</surname><given-names>A</given-names></name><name><surname>Hanhart</surname><given-names>J</given-names></name><name><surname>Schill</surname><given-names>C</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name><name><surname>Savic Prince</surname><given-names>S</given-names></name><name><surname>Wiese</surname><given-names>M</given-names></name><name><surname>Lardinois</surname><given-names>D</given-names></name><name><surname>Ho</surname><given-names>P-C</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Karanikas</surname><given-names>V</given-names></name><name><surname>Mertz</surname><given-names>KD</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Zippelius</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A transcriptionally and functionally distinct PD-1<sup>+</sup> CD8<sup>+</sup> T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade</article-title><source>Nature Medicine</source><volume>24</volume><fpage>994</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0057-z</pub-id><pub-id pub-id-type="pmid">29892065</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thommen</surname><given-names>DS</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>T Cell Dysfunction in Cancer</article-title><source>Cancer Cell</source><volume>33</volume><fpage>547</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.012</pub-id><pub-id pub-id-type="pmid">29634943</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumeh</surname><given-names>PC</given-names></name><name><surname>Harview</surname><given-names>CL</given-names></name><name><surname>Yearley</surname><given-names>JH</given-names></name><name><surname>Shintaku</surname><given-names>IP</given-names></name><name><surname>Taylor</surname><given-names>EJM</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Spasic</surname><given-names>M</given-names></name><name><surname>Henry</surname><given-names>G</given-names></name><name><surname>Ciobanu</surname><given-names>V</given-names></name><name><surname>West</surname><given-names>AN</given-names></name><name><surname>Carmona</surname><given-names>M</given-names></name><name><surname>Kivork</surname><given-names>C</given-names></name><name><surname>Seja</surname><given-names>E</given-names></name><name><surname>Cherry</surname><given-names>G</given-names></name><name><surname>Gutierrez</surname><given-names>AJ</given-names></name><name><surname>Grogan</surname><given-names>TR</given-names></name><name><surname>Mateus</surname><given-names>C</given-names></name><name><surname>Tomasic</surname><given-names>G</given-names></name><name><surname>Glaspy</surname><given-names>JA</given-names></name><name><surname>Emerson</surname><given-names>RO</given-names></name><name><surname>Robins</surname><given-names>H</given-names></name><name><surname>Pierce</surname><given-names>RH</given-names></name><name><surname>Elashoff</surname><given-names>DA</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title><source>Nature</source><volume>515</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/nature13954</pub-id><pub-id pub-id-type="pmid">25428505</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturi</surname><given-names>V</given-names></name><name><surname>Quigley</surname><given-names>MF</given-names></name><name><surname>Greenaway</surname><given-names>HY</given-names></name><name><surname>Ng</surname><given-names>PC</given-names></name><name><surname>Ende</surname><given-names>ZS</given-names></name><name><surname>McIntosh</surname><given-names>T</given-names></name><name><surname>Asher</surname><given-names>TE</given-names></name><name><surname>Almeida</surname><given-names>JR</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Davenport</surname><given-names>MP</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A mechanism for TCR sharing between T cell subsets and individuals revealed by pyrosequencing</article-title><source>Journal of Immunology (Baltimore, Md)</source><volume>186</volume><fpage>4285</fpage><lpage>4294</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1003898</pub-id><pub-id pub-id-type="pmid">21383244</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vijayan</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Teng</surname><given-names>MWL</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting immunosuppressive adenosine in cancer</article-title><source>Nature Reviews. Cancer</source><volume>17</volume><elocation-id>765</elocation-id><pub-id pub-id-type="doi">10.1038/nrc.2017.110</pub-id><pub-id pub-id-type="pmid">29162946</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yossef</surname><given-names>R</given-names></name><name><surname>Tran</surname><given-names>E</given-names></name><name><surname>Deniger</surname><given-names>DC</given-names></name><name><surname>Gros</surname><given-names>A</given-names></name><name><surname>Pasetto</surname><given-names>A</given-names></name><name><surname>Parkhurst</surname><given-names>MR</given-names></name><name><surname>Gartner</surname><given-names>JJ</given-names></name><name><surname>Prickett</surname><given-names>TD</given-names></name><name><surname>Cafri</surname><given-names>G</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy</article-title><source>JCI Insight</source><volume>3</volume><elocation-id>122467</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.122467</pub-id><pub-id pub-id-type="pmid">30282837</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Leng</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood</article-title><source>Inflammation</source><volume>35</volume><fpage>1773</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1007/s10753-012-9496-8</pub-id><pub-id pub-id-type="pmid">22752562</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer</article-title><source>OncoTargets and Therapy</source><volume>14</volume><fpage>2149</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.2147/OTT.S297272</pub-id><pub-id pub-id-type="pmid">33790578</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziani</surname><given-names>L</given-names></name><name><surname>Chouaib</surname><given-names>S</given-names></name><name><surname>Thiery</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>414</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00414</pub-id><pub-id pub-id-type="pmid">29545811</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77274.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Washington</named-content></addr-line><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2022.01.30.478375" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2022.01.30.478375"/></front-stub><body><p>This manuscript presents a computational approach to identify T-cells that can mount an immune response against tumors. The authors examine the presence of clusters of T cells with similar sequence as a surrogate for tumor antigen-specific responses. The identification of tumor-specific responses within the background of bystander T cell infiltration is an area of great current interest. This study provides solid support that T cell sequence clustering can be used to identify tumor-specific responses in vivo and in vitro.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77274.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Washington</named-content></addr-line><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Elhanati</surname><given-names>Yuval</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Chain</surname><given-names>Benny</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>University College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Isacchini</surname><given-names>Giulio</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an7q238</institution-id><institution>Univeristy of California, Berkeley</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.01.30.478375">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.01.30.478375v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Pinpointing the tumor-specific T-cells via TCR clusters&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Satyajit Rath as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Yuval Elhanati (Reviewer #1); Benny Chain (Reviewer #2); Giulio Isacchini (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Please include a description of the ALICE algorithm so the manuscript becomes self-sufficient.</p><p>2. ALICE is a powerful method since it can find reactive T cells without a background before sample. But for the scenarios in the paper, a before sample usually exists, which can help identify the reactive clusters and clones.</p><p>Are these samples used to inform ALICE? If not, it should be discussed how they can used to strengthen the analysis.</p><p>3. Please better describe the differences between different T-cell subgroups, which are sorted based on receptor such as IL2, IL21, etc. These descriptions should make the paper more accessible to the broader audience.</p><p>4. In the first result section, and in figure 1, it is shown that normalized ALICE hits increase following treatment. But it's not clear how this effect differs between responders and non-responders. This should be added as a figure or at least described in the text.</p><p>5. Melan A is a rather unusual TAA, because of the high precursor frequency of melan A specific T cells. Please include a discussion on this point in the Discussion section.</p><p>6. Please clarify the figure captions and descriptions (in the text) by thoroughly addressing all comments from reviewer #3.</p><p>7. Please clarify the online methods by thoroughly addressing the comments from reviewer #4.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>– In the last paragraph of the introduction, a comma or space seems to be missing between CD8<sup>+</sup> and CD39+PD1+, at least if indeed the CD39+PD1+ refers also to the CD4<sup>+</sup> cells.</p><p>– Also in the same paragraph, the acronym TAA is used, but it's not defined outside of the abstract.</p><p>– ALICE is a powerful method since it can find reactive T cells without a background before sample. But for the scenarios in the paper, a before sample usually exist, that can help identify the reactive clusters and clones. Is it used in some way in ALICE? If not, it should at least be discussed how it can used to strengthen the analysis.</p><p>– Various cytokines and receptors such as IL2, IL21, CD137 and CD39 are used to separate T cells of interest, often without describing their function and role. For the wider audience in <italic>eLife</italic>, these should be described in context, so the different groups of T cells used are clear.</p><p>– In the first Results section, and in figure 1, normalized ALICE hits are shown to increase following treatment. But it's not clear how this effect changes between responders and non-responders. This should be added as a figure or at least described in the text.</p><p>– The last section in the results seems to have little relation to the main analysis method in the paper, and maybe should be omitted.</p><p>– In the methods section &quot;Cluster analysis of TIL TCRβ repertoires&quot;, the following sentence is unclear – &quot;we normalized the number of hits between samples based on the number of the top-frequency input clonotypes.&quot;</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>This study is on the whole convincing and interesting. I felt that the figures, while aesthetically pleasing, could have been explained in more detail, and were somewhat hard to follow.</p><p>1. I would like to know more about the set of matching TCRs in VDJdb – how many, against what antigens, are the annotated TCRs themselves highly clustered.</p><p>2. For example, in 1C, in the clusters, does this mean that all TCRs were also found in VDJdb? Or does this mean that there was only a tiny cluster and so one hit was close to 100%? What is the individual red dot in panel 1 d? What exactly does the y axis in f mean? Is this the proportion of TILs which fall in an ALICE cluster?</p><p>3. A bit more detail on running the ALICE pipeline would be helpful. I couldn't see anything about this in Methods.</p><p>4. A bit more explanation of the y axes in general would be helpful. What exactly is the calculation for normalised ALICE hits, etc.</p><p>5. I like the point in Figure 2 that phenotype is sometimes not enough, but needs sequencing alongside. This is an important message to the field.</p><p>6. I don't quite understand the gigantic clusters of TCRs in Figure 3, and why they all seem to be red. This comes back to point 1 I think. I don't quite understand how stimulating a population in vivo gives rise to these huge clusters, all within 2 aa of each other? Maybe I am not understanding this figure – again a bit more detail saying what exactly is being done and shown would hugely improve the impact.</p><p>7. Melan A is a rather unusual TAA, because of the high precursor frequency of melan A specific T cells. Might be worth discussing this in a bit more detail in the Discussion.</p><p>In summary, this is a very interesting and important piece of work. But more thought on clarifying what is being done, and how it is being shown would hugely improve the study and increase the number of readers.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Some more explanations (in the main text as well) on the Alice algorithm would be useful for those that are not familiar with the approach.</p><p>Moreover, also in the Online Methods some clarifications are needed:</p><p>– It is mentioned that the number of Alice hits depends on the initial variability of the repertoire: can you show it with an SI figure?</p><p>– Where does the normalization with respect to top-frequency clones comes from? Is an heuristic approach or has it a proper basis? Why does it work?</p><p>– Is the default pgen model used? Why not inferring a pgen model for each of the patients?</p><p>– The Alice algorithm should work with clusters of hamming distance one. Why visualizing clusters of hamming distance up to 2?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77274.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Please include a description of the ALICE algorithm so the manuscript becomes self-sufficient.</p></disp-quote><p>We added a brief description to the Introduction, and also expanded in the Methods section.</p><disp-quote content-type="editor-comment"><p>2. ALICE is a powerful method since it can find reactive T cells without a background before sample. But for the scenarios in the paper, a before sample usually exists, which can help identify the reactive clusters and clones.</p><p>Are these samples used to inform ALICE? If not, it should be discussed how they can used to strengthen the analysis.</p></disp-quote><p>We discuss this point in detail in our answer to the corresponding Reviewer 2 question.</p><disp-quote content-type="editor-comment"><p>3. Please better describe the differences between different T-cell subgroups, which are sorted based on receptor such as IL2, IL21, etc. These descriptions should make the paper more accessible to the broader audience.</p></disp-quote><p>We added brief explanations about each marker or cytokine.</p><disp-quote content-type="editor-comment"><p>4. In the first result section, and in figure 1, it is shown that normalized ALICE hits increase following treatment. But it's not clear how this effect differs between responders and non-responders. This should be added as a figure or at least described in the text.</p></disp-quote><p>No difference between responders and non-responders. Added to the text, discussed in our answer to the corresponding Reviewer 2 question.</p><disp-quote content-type="editor-comment"><p>5. Melan A is a rather unusual TAA, because of the high precursor frequency of melan A specific T cells. Please include a discussion on this point in the Discussion section.</p></disp-quote><p>Please see our answer to the corresponding Reviewer 3 question.</p><disp-quote content-type="editor-comment"><p>6. Please clarify the figure captions and descriptions (in the text) by thoroughly addressing all comments from reviewer #3.</p></disp-quote><p>Worked on this, thank you.</p><disp-quote content-type="editor-comment"><p>7. Please clarify the online methods by thoroughly addressing the comments from reviewer #4.</p></disp-quote><p>Worked on this as well, thank you.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>– In the last paragraph of the introduction, a comma or space seems to be missing between CD8<sup>+</sup> and CD39+PD1+, at least if indeed the CD39+PD1+ refers also to the CD4<sup>+</sup> cells.</p></disp-quote><p>Corrected, thank you.</p><disp-quote content-type="editor-comment"><p>– Also in the same paragraph, the acronym TAA is used, but it's not defined outside of the abstract.</p></disp-quote><p>Corrected, thank you.</p><disp-quote content-type="editor-comment"><p>– ALICE is a powerful method since it can find reactive T cells without a background before sample. But for the scenarios in the paper, a before sample usually exist, that can help identify the reactive clusters and clones. Is it used in some way in ALICE? If not, it should at least be discussed how it can used to strengthen the analysis.</p></disp-quote><p>Indeed, the beauty of the ALICE approach is that – since it allows to identify convergent TCRs involved in the current response – it allows to get the useful information “from single repertoire snapshots”. In the past, we successfully used ALICE to identify autoimmunity-related TCR clusters, as well as Yellow-fever specific clusters, all from single snapshots (https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000314).</p><p>Here, we use non-DP and bulk (FFT) repertoires as background for comparison. On Figure 3b,c, the FFT represent non-cultured TCR repertoires, so essentially these are “before” samples if you compare with the cultured cells on the same panels. Figure 3a also includes non-cultured DP CD8<sup>+</sup> and non-DP CD8<sup>+</sup> repertoires that also represent “before” samples.</p><p>Furthermore, on Figure 3d,e, where we analyse clonotypes that preferentially expanded in presence of IL-21 and IL-2<sub>low</sub> (with or without nivolumab and IFNɣ) compared to pan-activating IL-2<sub>high</sub> conditions, we then check the presence of such clonotypes in initial non-cultured DP CD8<sup>+</sup> and non-DP CD8<sup>+</sup> repertoires – that is, again, in “before” samples. Thus, we actually use the background before samples, not in the ALICE approach but to evaluate the informativeness of the obtained clusters.</p><p>We worked on the text to make it clear, thank you for the note.</p><disp-quote content-type="editor-comment"><p>– Various cytokines and receptors such as IL2, IL21, CD137 and CD39 are used to separate T cells of interest, often without describing their function and role. For the wider audience in eLife, these should be described in context, so the different groups of T cells used are clear.</p></disp-quote><p>We added brief description of cytokines used for TILs culturing:</p><p>“We next investigated the effect of distinct TIL culture conditions on the expansion of tumor-reactive T cells, including concentration of IL-2 (stimulates expansion of both conventional and regulatory T cells), and presence of IL-21 (plays a key role in the development and maintenance of memory CD8<sup>+</sup> T cells, inhibits T<sub>reg</sub> proliferation), anti-PD-1 antibody (blocks inhibitory interaction of T cells’ PD-1 with PD-L1), and IFNɣ (activates antigen presentation and supports type 1 immune response). Four distinct TIL culture conditions included…”</p><p>We also briefly added:</p><p>“Certain cell-surface markers of ongoing and chronic activation such as PD-1, CD39, CD69, CD103, or CD137 may also help to delineate T cell subpopulations (typically CD8<sup>+</sup>) that are enriched for clonally-expanded tumor-reactive T cells…”</p><disp-quote content-type="editor-comment"><p>– In the first Results section, and in figure 1, normalized ALICE hits are shown to increase following treatment. But it's not clear how this effect changes between responders and non-responders. This should be added as a figure or at least described in the text.</p></disp-quote><p>Thank you for the note. We checked but found no differences. The following was added to the text:</p><p>“The number of cluster-related clonotypes significantly increased after therapy in both cohorts (p = 0.019 and 0.038, respectively; Figure 1a,b), which might reflect treatment-dependent expansion of convergent antigen-specific TILs. At the same time, no statistically significant differences were observed between responders, stable disease, and progressive disease groups.”</p><disp-quote content-type="editor-comment"><p>– The last section in the results seems to have little relation to the main analysis method in the paper, and maybe should be omitted.</p></disp-quote><p>For a part of the readership, this manuscript is not only about bioinformatics, but also about practical aspects of TIL-based therapy.</p><p>Furthermore, this section of results shows that the T cell expansion condition that showed highest enrichment with tumor-specific TCR clusters as shown by ALICE, at the same time yields preferable T cell subsets composition – in terms of low Treg, high memory, and high CD8<sup>+</sup> T cells proportions.</p><p>Thus, we believe that this part is a valuable piece of the manuscript that should preferably remain in the main text.</p><disp-quote content-type="editor-comment"><p>– In the methods section &quot;Cluster analysis of TIL TCRβ repertoires&quot;, the following sentence is unclear – &quot;we normalized the number of hits between samples based on the number of the top-frequency input clonotypes.&quot;</p></disp-quote><p>Thank you for the note, it was not neither clear nor formally correct. Now added Supplementary Figure 1d and changed to a more clear description:</p><p>“The number of ALICE hits strongly depends on the initial variability of the TCR repertoire (Supplementary Figure 1d). To account for this, “Normalized ALICE hits” metric was calculated by dividing the number of ALICE hits by the number of clonotypes in initial input.”</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>This study is on the whole convincing and interesting. I felt that the figures, while aesthetically pleasing, could have been explained in more detail, and were somewhat hard to follow.</p><p>1. I would like to know more about the set of matching TCRs in VDJdb – how many, against what antigens, are the annotated TCRs themselves highly clustered.</p></disp-quote><p>Different ALICE clusters had different counts of VDJdb-matching clonotypes, that matched variable numbers of VDJdb entries. For example, ALICE clusters from Figure 2h in the manuscript matched to a set of MLANA-specific VDJdb entries:</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-sa2-fig1-v3.tif"/></fig><p>Here you can see the graphs and logos for TAA-specific clusters from Figure 3a:</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-sa2-fig2-v3.tif"/></fig><fig id="sa2fig3" position="float"><label>Author response image 3.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-sa2-fig3-v3.tif"/></fig><p>Notably, all matches had specificity to the same antigen and same HLA-restriction, which coincided with the HLA-status of the patient.We have also registered the presence of ALICE cluster, all members of which matched to VDJdb TCRs recognizing NLVPMVATV epitope of pp65 CMV protein in HLA-A*02 context.</p><fig id="sa2fig4" position="float"><label>Author response image 4.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77274-sa2-fig4-v3.tif"/></fig><p>There were also some minor clusters that were composed of clonotypes matching VDJdb TCRs with different specificities. We implied that the whole cluster is antigen specific only if all its VDJdb-matched members corresponded to TCRs with the same antigen specificity.</p><disp-quote content-type="editor-comment"><p>2. For example, in 1C, in the clusters, does this mean that all TCRs were also found in VDJdb? Or does this mean that there was only a tiny cluster and so one hit was close to 100%? What is the individual red dot in panel 1 d? What exactly does the y axis in f mean? Is this the proportion of TILs which fall in an ALICE cluster?</p></disp-quote><p>On panel 1с we compare cumulative frequency of TCRs matched to melanoma-specific entries in VDJdb in the total TCR repertoire versus cumulative frequency of such clonotypes among ALICE hits. The purpose of such comparison is to show that ALICE hits are enriched with potentially tumor-reactive clonotypes.</p><p>Each dot on panel 1d represents an individual TCR clonotype. Dot size is proportional to the clonotype frequency in the corresponding TCR repertoire. VDJdb-matched TAA-specific clonotypes are colored in red.</p><p>Regarding 1e,f panels – each dot represents one TCR cluster. The Y axis shows the size of corresponding clusters (e.g. cumulative frequency of clonotypes within a cluster, % of the whole repertoire).</p><p>We worked on the figure legend to make these things more clear.</p><disp-quote content-type="editor-comment"><p>3. A bit more detail on running the ALICE pipeline would be helpful. I couldn't see anything about this in Methods.</p></disp-quote><p>We expanded the Methods section to give more details on ALICE. Some basic description was also added to the Introduction.</p><disp-quote content-type="editor-comment"><p>4. A bit more explanation of the y axes in general would be helpful. What exactly is the calculation for normalised ALICE hits, etc.</p></disp-quote><p>Thank you for the comment, we worked on the figures and text to make these (complicated) things more clear.</p><disp-quote content-type="editor-comment"><p>5. I like the point in Figure 2 that phenotype is sometimes not enough, but needs sequencing alongside. This is an important message to the field.</p></disp-quote><p>Yes, that’s really a critically important message, thank you for the note.</p><disp-quote content-type="editor-comment"><p>6. I don't quite understand the gigantic clusters of TCRs in Figure 3, and why they all seem to be red. This comes back to point 1 I think. I don't quite understand how stimulating a population in vivo gives rise to these huge clusters, all within 2 aa of each other? Maybe I am not understanding this figure – again a bit more detail saying what exactly is being done and shown would hugely improve the impact.</p></disp-quote><p>Clusters in Figure 3 represent convergent clonotypes found in TILs cultured in various cytokine environments, one circle represents 1 clonotype in one condition. Red colour represents clonotypes that were matched to known TAA-specific clonotypes (in VDJdb) allowing one-aa mismatch (Hamming distance ≤1, worked further on this figure), thus red clusters are the ones dominated by clonotypes with identified specificity. We don’t merge clonotypes that come from different samples (corresponding to culture conditions or sorted populations). So the more different variables we analyse, the bigger the clusters will be. Despite this bias, this is a clear way to visualise how culture conditions affect the structure of convergent TCR clusters. For instance, we can see that the top-left cluster is relatively better expanded in IL21+Nivolumab+ culturing conditions.</p><disp-quote content-type="editor-comment"><p>7. Melan A is a rather unusual TAA, because of the high precursor frequency of melan A specific T cells. Might be worth discussing this in a bit more detail in the Discussion.</p></disp-quote><p>We agree that this is a point that needs to be addressed. Added to discussion:</p><p>“The cumulative frequency of such Melan-A specific clusters within the CD8<sup>+</sup> DP population was only slightly lower than the total frequency of all identified Melan-A-specific TCRs, indicating that our approach was able to identify most of the high-frequency tumor-specific clonotypes. It should be noted that Melan A-specific T cells have unusually high frequency in melanoma patients, and even in healthy individuals with HLA-A*02 allele. Also, Melan A-specific T cell clones in some cases represent predominant population in melanoma TILs and are present at high frequency in melanoma-infiltrated lymph nodes. This may mean that using Melan A-specific clonotypes as a model is overestimating the sensitivity of our approach. On the other hand, in our data, as well as in public datasets we used in this paper, there are other clusters of comparable size that are not identified as Melan A-specific, which means that there are other specificities with similar behaviour. &quot;</p><disp-quote content-type="editor-comment"><p>In summary, this is a very interesting and important piece of work. But more thought on clarifying what is being done, and how it is being shown would hugely improve the study and increase the number of readers.</p></disp-quote><p>Thank you! We hope we now improved the manuscript following your very useful comments.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Some more explanations (in the main text as well) on the Alice algorithm would be useful for those that are not familiar with the approach.</p></disp-quote><p>We added general description of ALICE to the Introduction section, and more details to Methods.</p><disp-quote content-type="editor-comment"><p>Moreover, also in the Online Methods some clarifications are needed:</p><p>– It is mentioned that the number of Alice hits depends on the initial variability of the repertoire: can you show it with an SI figure?</p></disp-quote><p>Yes, thank you for the point. We added the Supplementary Figure 1d that shows this correlation.</p><disp-quote content-type="editor-comment"><p>– Where does the normalization with respect to top-frequency clones comes from? Is an heuristic approach or has it a proper basis? Why does it work?</p></disp-quote><p>Thank you for the note, it was not neither clear nor formally correct. Changed to a more clear description:</p><p>“The number of ALICE hits strongly depends on the initial variability of the TCR repertoire (Supplementary Figure 1d). To account for this, “Normalized ALICE hits” metric was calculated by dividing the number of ALICE hits by the number of clonotypes in initial input.”</p><disp-quote content-type="editor-comment"><p>– Is the default pgen model used? Why not inferring a pgen model for each of the patients?</p></disp-quote><p>Indeed, the default VDJ recombination model from Murugan et al. 2012 was used. According to this work, Pgen predicted by proposed default model are overall consistent across population. Moreover, implementation of this model was proven to be valid in seminal ALICE paper.</p><disp-quote content-type="editor-comment"><p>– The Alice algorithm should work with clusters of hamming distance one. Why visualizing clusters of hamming distance up to 2?</p></disp-quote><p>Right, thank you for your note. Should be Hamming distance &lt; = 1, we corrected and re-draw the clusters on Figure 3. On Figures 1 and 2 it was Hamming distance &lt; = 1 initially.</p></body></sub-article></article>